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Abstract 
There is wide interest in using the unique properties of microfluidic environments for the 
production of fine chemicals and pharmaceuticals.  Compared to bench top synthesis, 
microfluidic systems engender the significant advantage of superior control of chemical 
state functions.  The ability to tune reagent concentration, reaction temperature, mixing 
time, and residence time allows reactions to run more efficiently thus generating products 
of higher yield and purity.  While several microfluidic platforms are actively developed 
in both academic and industrial laboratories, vast majority are based in rigid materials 
and have only demonstrated improvements in yield for single reaction steps. 
 
Multilayer Soft Lithography has already found much use in the biological field.  For 
example, several complex devices based upon functional modules have been developed 
for protein crystallography, nucleic acid processing, FACS, enzyme screening tools, and 
PCR.  Because of the many similarities between operations in organic synthesis and 
biochemistry, there is widespread interest in extending these newfound successes in the 
realm of biology to the realm of automated chemical synthesis.    
 
This thesis focuses on the application of Multilayer Soft Lithography to the development 
and adaptation of microfluidic tools for chemical synthesis.  The first successful 
demonstration of multistep organic synthesis in integrated microfluidics was the 
production of a molecular image probe, 2-deoxy-2-[18F]fluoro-d-glucose.  The nanogram 
level dosage for imaging probes makes them attractive candidates for small scale 
synthesis of microfluidics.  The reduced synthesis time achieved by using a microfluidic 
device is especially important because of the relatively short half-life of the radioactive 
fluoride.   
 
While PDMS remains the material of choice for devices in biological applications, its 
incompatibility with many nonpolar organic solvents limits the types of reactions that can 
be performed with it.  Through collaboration with Joseph DeSimone’s group at the 
University of North Carolina at Chapel Hill, a suitable substitute for PDMS was found in 
perfluoropolyethers (PFPE).  A solvent-resistant integrated microfluidic device was 
developed for solid-phase oligonucleotide synthesis using conventional phosphoramidite 
chemistry.  To confirm that the microfluidic platform in development can indeed become 
a valuable tool in the field of synthetic biology, a 16 column parallel oligonucleotide 
synthesizer was manufactured that is capable of producing 16 distinct sequences up to 40 
bases in length to be used in gene assembly.  Successful construction of a gene fragment 
was completed from a mixture of unpurified and unamplified oligonucleotides 
synthesized on the device. 
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Chapter 1  
OVERVIEW 
Introduction 
There is great interest in exploiting the unique properties of microfluidic environments 
for producing fine chemicals and pharmaceuticals (1--3). The reduced length scale 
associated with microfluidic architecture allows access to an extraordinary physical 
regime that is often counterintuitive yet advantageous to experiences in the macroscopic 
world.  
 
The most notable effects that manifest in this microenvironment are diminished inertial 
nonlinearity, enhanced heat transfer, increased surface-to-volume ratio and reduced 
diffusion time (4).  In fact, there are many examples where microreactors have been used 
to take advantage of each of these effects to facilitate chemical processes. 
 
With the decline in inertial forces, fluid flows at low Reynolds Numbers are almost 
strictly laminar.  Two immiscible fluids can stream side-by-side in concurrent or 
countercurrent flow arrangements without mixing.  By choosing two liquids that have 
different partition coefficients to the molecule of interest, continuous extraction of solute 
from one phase to another is achievable as demonstrated by Aota et al. (5).  
 
Also, as a direct result of miniaturization, typical microfluidic devices have reduced 
thermal masses.  High thermal transfer efficiencies allow many exothermic or high 
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temperature reactions to be performed with unprecedented control.  Fluorine chemistry 
has always been a field plagued with safety issues such as thermal runaway and 
explosions because the change in enthalpy from a carbon-hydrogen bond to carbon-
fluorine bond is so extreme.  De Mas et al. have reported direct fluorination of toluene 
under isothermal conditions at room temperature, which looks promising for future 
commercialization (6).    
 
 The large surface-to-volume ratios characteristic of microfluidic reactors are 
exceptionally well suited for performing heterogeneous chemistry.  Typically, these 
reactions are difficult to conduct when compared to homogeneous reactions because the 
efficiency of interaction and mass transfer between different phases is low.  To accelerate 
multiphase catalytic reactions, high interfacial area between the two or three reacting 
phases needs to be produced through vigorous stirring.  By switching from a macro scale 
setting to microfludics, the interfacial area per unit of volume can increase by 3 to 4 
orders of magnitude.  Through incorporation of a catalyst into the channel surfaces, 
Kobayashi et al. reported triphasic hydrogenation with space-time yield considerably 
higher than that of laboratory-scale reactions (7).     
 
In typical microfluidic devices, mixing is accomplished though diffusion.  However, 
unlike in the macroscopic world, where diffusive mixing is highly inefficient, diffusion 
time can be very small at a micron length scale.  A further advantage of diffusive mixing 
is that it can be spatially controlled.  By manipulating the width of the diffusive length 
and the flow rate of the streams, one can not only achieve mixing times of less than 10 
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microseconds, but can also determine the residence time from the distance that the 
mixture has traveled since it first converged.  In fact, ultra-fast chemical reactions have 
been probed through the use of hydrodynamic focusing (8,9).   
 
The above examples provide persuasive arguments for using microfluidic systems in 
chemical synthesis.  Compared to bench-top synthesis, microfluidic systems engender the 
significant advantage of superior control of chemical state functions.  The ability to tune 
reagent concentration, reaction temperature, mixing time, and residence time allows 
reactions to run more efficiently thus generating products of higher yield and purity.  
However, currently most applications are limited to the implementation of individual 
reaction units to demonstrate enhanced performance compared with their macroscale 
counterparts; to date, applications involving total synthesis of molecular compounds 
involving multiple reactions steps with intermediate workup are almost nonexistent. 
 
There are many reasons why adaptation of microfludics to complete molecular synthesis 
is not yet possible.  Among the major challenges is the inability to manipulate and 
process diverse reagents and solvents in an efficient manner that can be coupled to 
perform complex multi-step synthesis.  In this regard, microfluidic systems with 
integrated microvalves represent a device architecture that is much better suited to the 
execution and automation of multiple, parallel, and sequential chemical processes than 
the continuous flow devices that are more prevalent in the current literature.     
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That is not to say that continuous flow reactors are inferior.  The use of microfluidics in 
production applications will ultimately be determined by their ability to generate useful 
volumes of product on short time scales, and continuous flow reactors in combination 
with parallelization (scale out approach) have greater potential for large scale production 
of a single compound.  However, there exist many applications in which the ability to 
generate minute amounts of large number of diverse products is desirable, especially in 
lead generation for drug discovery or oligonucleotide synthesis for gene or genome 
assembly (10,11).  The work presented here will attempt to fill that niche of molecular 
synthesis with integrated microfluidics.     
Context 
The technologies used in this thesis utilize and build upon the multilayer soft lithography 
(MSL) process developed in the Quake group by Unger et al. (12).  MSL uses soft 
elastomeric rubber such as polydimethylsiloxane (PDMS) to fabricate active monolithic 
valves,  which are the fundamental building blocks used to assemble higher level fluidic 
components such as pumps, mixers, columns, and multiplexers (13).  These high level 
components (or modules) can then be incorporated to perform complex operations in 
seamless fashion much like integrated circuits.   
 
At the initiation of this work, MSL has already found much use in the biological field.  
For example, several complex devices based upon functional modules have been 
developed for protein crystallography, nucleic acid processing, FACS, enzyme screening 
tools, and PCR (14--19).   Some, such as devices for protein crystal growth and digital 
PCR, were in the early stages of commercialization.  Because of the many similarities 
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between operations in organic synthesis and biochemistry, there is widespread interest in 
extending these newfound successes in the realm of biology to the realm of automated 
chemical synthesis.     
 
The focus of this thesis is the application of multilayer soft lithography to the 
development and adaptation of microfluidic tools for chemical synthesis.  The first 
successful demonstration of multistep organic synthesis in integrated microfluidics was 
the production of a molecular image probe, 2-deoxy-2-[18F]fluoro-D-glucose.  The 
nanogram level dosage for imaging probes makes them attractive candidates for small 
scale synthesis of microfluidic.  Gas permeability of PDMS matrix was exploited for 
successful solvent exchange through evaporation.  The reduced synthesis time achieved 
by using a microfluidic device is especially important because of the relatively short half-
life of the radioactive fluoride.  Overall, it provides a glimpse of the capabilities of 
integrated elastomeric-based microfluidic by successfully proving its utility for 
synthesizing molecular probes.   
 
While PDMS remains the material of choice for devices in biological applications, its 
incompatibility with many nonpolar organic solvents limits the types of reactions that can 
be performed with it.  The field of chemical synthesis could benefit tremendously from 
the development of solvent-resistant elastomeric microfluidic devices.  Through 
collaboration with Joseph DeSimone’s group at the University of North Carolina at 
Chapel Hill, a suitable substitute for PDMS was found in perfluoropolyethers (PFPE).  
With the help of Piero Castrataro, who perfected the fabrication protocol for PFPE 
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devices, a solvent-resistant integrated microfluidic device was developed for solid-phase 
oligonucleotide synthesis using conventional phosphoramidite chemistry. 
 
To confirm that the microfluidic platform in development can indeed become a valuable 
tool in the field of synthetic biology, a 16 column parallel oligonucleotide synthesizer 
was manufactured that is capable of producing 16 distinct sequences up to 40 bases in 
length to be used in gene assembly.  Successful construction of a gene fragment was 
completed from a mixture of unpurified and unamplified oligonucleotides synthesized on 
the device.     
 
In order to produce the tens of thousands of distinct oligonucleotide strands needed for 
genome synthesis, several technical issues need to be addressed.  The ability to address 
appropriate reactors in each synthetic step becomes increasingly difficult as the number 
of reactors increases.   Two strategies are devised to overcome such problems.  The first 
strategy involves the adaptation of a demultiplexer (demux) to address multiple valves 
from a single pressure input, termed “control of control” by others.   The second strategy 
takes advantage of the ease of the design and fabrication of PDMS devices to 
manufacture synthesizers that are tailored to specific sequences.  While the startup and 
fabrication costs of conventional glass or silica microfluidic devices make it unfeasible to 
design and make devices for single use customized applications, the simplicity of MSL 
fabrication makes such strategies reasonable. 
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Organization and Collaborations 
Chapter 2 describes an integrated microfluidic device designed for rapid synthesis of a 
[18F]radio-labeled molecular imaging probe, 2-deoxy-2-[18F]fluoro-D-glucose 
([18F]FDG)(20)  on a nanogram scale that is sufficient for PET studies in mice.  This 
device integrates valves, peristaltic pumps, an anion exchange column, and reaction loops 
to perform several sequential processes―fluoride concentration, fluorination, solvent 
exchange, and hydrolytic deprotection.  A modular approach is taken in the design of the 
device.  High level components, such as the anion exchange column and reactions loops 
are first constructed, tested, and optimized for each process before integration.   The 
results of the development of each component module are presented.  The modules are 
then integrated and the combined design is simplified down to its final state.  Work 
involving fluorination and hydrolytic deprotection was done in collaboration with 
Guodong Sui from Hsian-Rong Tseng’s group at the University of California, Los 
Angeles.  [18F]fluoride from proton-bombarded [18O]water was provided by Nagichettiar 
Satyamurthy at The Crump Institute for Molecular Imaging.  A second-generation device 
capable of synthesizing [18F]FDG dose sufficient for several human PET scans 
was designed by Arkadij Elizarov.  The product from the second-generation device was 
utilized for microPET- and microCT-based molecular imaging of two mouse models. 
 
Chapter 3 describes an automated DNA synthesizer made of PFPE (perfluoropolyether) 
that is capable of synthesizing 60 pmol of DNA oligonucleotides up to 20 nucleotides in 
length with substantial savings in reagent consumption (by 60-fold).  The reaction cycles 
performed are adopted from the widely used phosphoramidite method (21,22).  The 
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device remains robust and functional even after hours of exposure to organic solvents 
such as dichloromethane that are incompatible with PDMS.  Electrospray ionization 
liquid chromatography mass spectrometry is used to characterize synthesized 
oligonucleotides.  The sequence is further confirmed through melting curve measure with 
matched and mismatched complementary strands.  Fabrication of PFPE devices was 
developed and provided by Piero Castrataro, and the adaptation of phosphoramidite 
chemistry was done by Yanyi Huang. 
 
Chapter 4 describes a second-generation oligonucleotide synthesizer made of PDMS that 
can produce sixteen distinct sequences in parallel.  The scale of synthesis is increased to 
~ 100 pmol so there are enough products for both standard analytical methods as well as 
gene assembly without further amplification.  The reagent consumption on a per 
sequence basis is further reduced by 2-fold compared with a previous generation single 
reactor microfluidic DNA synthesizer.  The development of a new deblocking solution 
was necessary due to dichloromethane’s incompatibility with PDMS.  The deblocking 
efficiency of the new deblocking solution is calculated to be greater than 98.6%, which is 
substantially higher than that of many other PGA systems (23).  We also added an 
additional capping step that was not used in our original synthesis of short nucleotides.  
By capping unreacted bases, we prevented truncated sequence from extending further and 
were able to synthesize oligonucelotides up to 40 bases in length (twice as long as our 
previous devices).  A mixture of 17--24-mers oligos were also synthesized and used in a 
ligation-mediated assembly method to generate a gene fragment from Bacillus cereus 
approximately 200 base pairs in length. Sequencing revealed that the error rate is 
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consistent with other assembly methods using unpurified oligonucleotides (24).  The gene 
assembly method used was developed by Thomas Snyder and Yinthai Chan.  PCR and 
cloning of the assembled product was done under guidance from Thomas Snyder. 
 
Chapter 5 describes future strategies for further parallelization of DNA synthesis.  Using 
current device architectures, the number of reactor columns that can be individually 
addressed is severely limited by the number of solenoid valves.  Two solutions are 
devised to overcome such problem.  The first solution involves the adaptation of “control 
of control”, first implemented by Todd Thorsen in our group.   The second strategy takes 
advantage of the ease of the design and fabrication to make custom synthesizers that are 
tailored to specific sequences.  Instead of making the reactors individually addressable 
and having an outside program control each valve depending on the sequence, 
information about the specific sequences are directly embedded into the control lines of 
the device.  The difficulty of constructing reactor columns with uniform load and flow 
rates presents another problem.  While dramatic improvements have been made for the 
device described in Chapter 4, it is difficult to envision a similar column array scaling up 
to over 100 columns.  Some work has been done using sol-gel technologies to make the 
PDMS surface more glass like, thus allowing further coupling of linker directly onto the 
column surfaces.  
10 
 
 
Chapter 2  
SYNTHESIS OF POSITRON EMISSION TOMOGRAPHY IMAGING PROBES 
USING ELASTOMERIC-BASED INTEGRATED MICROFLUIDICS 
Introduction  
Imaging science has grown exponentially during the past three decades.  Many imaging 
techniques developed during this period have become indispensable both in research and 
clinical use.  Positron emission tomography (PET), a nuclear imaging technique that uses 
the unique decay characteristics of radionuclides that decay by positron emission, is one 
such technique.  The molecular compounds of interest are labeled with radionuclides and 
then introduced into the body and distributed in tissues.  When the radioactive atom on a 
molecule decays, a positron is ejected from the nucleus.  The positron will combine with 
a surrounding electron and annihilates into two high energy photons that are emitted 
simultaneously in opposite directions.  A PET scanner detects and localizes these events 
to reconstruct them into a three-dimensional tomographic image where signal intensity is 
proportional to the amount of radionuclide.    
 
PET’s molecular diagnostics of disease is distinct from anatomical diagnostics using 
structural imaging techniques such as X-ray computed tomography (CT) and magnetic 
resonance imaging (MRI).  In many ways, molecular imaging is superior to structural 
imaging for diseases because it provides a way to study the biological process of disease 
directly, even before the disease has the time to manifest itself anatomically.  For 
example, the loss of regulated expression of genes will precede visible tumor growth of 
cancers by many years or even decades (25,26).  The incorporation of molecular imaging 
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techniques to aid in the discovery and study of biochemical abnormalities leading to 
diseases would greatly aid in the detection and treatment of diseases. Indeed, advances in 
PET technologies and imaging probes for humans and small animals are extending into 
the realm of drug discovery and development, and have great potential to accelerate these 
processes (27,28). 
 
A key component in any successful molecular imaging is that the molecular probe 
specifically targets the process of interest in the body.  The probes must be safe, not alter 
the process being studied, be able to reach the target in sufficient concentration, and be 
retained long enough to be detected. A successful development of an imaging probe is an 
iterative process that first requires one to identify a specific receptor site, synthesize a 
molecular agent for that site, and then label that agent with a radioisotope.  While the 
concept is simple, the process can be arduous and complex.   The identification of 
molecular imaging targets and the development of new radiolabeled molecular probes for 
those targets are crucial for expanding the capability of in vivo molecular imaging for 
biological research, molecular diagnostics, and drug discovery.  The broad range of 
radiolabeled molecular probes needed in various applications would benefit greatly from 
optimized synthetic approaches so that they can be obtained rapidly, in high 
radiochemical yields, with flexible structural diversity, and at low cost.  
 
The synthesis of the [18F]-labeled molecular imaging probe 2-deoxy-2-[18F]fluoro-D-
glucose ([18F]FDG) in an integrated microfluidic chip was chosen as a proof of principle 
since it is a widely used radiopharmaceutical with over a million patient doses produced 
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in 2004 (PETNet Radiopharmaceuticals, private communication). The short half-life of 
[18F]fluorine makes rapid synthesis of doses essential, and the synthetic process includes 
common steps required in many chemical syntheses, including the preparation of other 
radiolabeled molecular imaging probes.  The nanogram mass of PET molecular imaging 
probes administered to subjects is ideal for miniaturized architecture of integrated 
microfluidics. Thus, the multi-step synthesis of [18F]FDG and other PET probes 
represents an interesting opportunity for integrated microfluidics chips.  
 
This chapter describes two integrated microfluidic devices that were developed in an 
effort to automate and streamline molecular probe synthesis on chip.  The first-generation 
device (Figure 2-1) is capable of executing the five chemical processes of the syntheses 
of both [18F]FDG and [19F]FDG within an anion exchange column and a nanoliter scale 
reaction vessel.  Each of the components and their operation procedure will be dealt with 
in more detail in the subsequent sections.  More importantly, it demonstrates that the 
implementation of sequential chemical steps, variable chemical environments, and 
variable physical conditions on a single chip is possible using elastomeric-based 
integrated microfluidic platform.  The device is also designed to produce sufficient 
quantities (100--200 μCi corresponding to a few nanograms) of [18F]FDG  for mouse 
imaging.  The 2nd-generation device (Figure 2-9) can synthesize larger [18F]FDG doses.  
The   coin-shaped reactor (5 μL volume) is much larger compared to the 40 nL volume 
reactor volume for the previous device. It was used to synthesize 1.74 mCi [18F]FDG 
sufficient for several mice experiments and can ultimately synthesize large quantities (i.e., 
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100 mCi) of [18F]FDG for imaging patients.  However, the concentration of fluoride is 
performed on a separate device.     
Overview of  2-Deoxy-2-fluoro-D-glucose (FDG) Synthetic Steps 
The production (29) of [18F]FDG is based on 5 sequential chemical processes (Figure 2-1 
A): (i) concentration of the dilute [18F]fluoride solution (1–10 ppm) obtained from the 
proton bombardment of [18O]water with a cyclotron; (ii) solvent exchange from water to 
anhydrous acetonitrile; (iii) [18F]fluoride substitution of the D-mannose triflate precursor 
in dry acetonitrile; (iv) solvent exchange back to water; and (v) acidic hydrolysis of the 
fluorinated intermediate to obtain [18F]FDG.  Presently, [18F]FDG is routinely produced 
in about 50 min using commercial synthesizers (30).  These automated synthesizers have 
a physical size of approximately 80 × 60 × 40 cm, and can produce ~ 10 to 100 doses for 
a human in a single run.  Inevitably, a considerable decrease in the radiochemical yield of 
the resulting probe must be tolerated because of the relatively short half-life of 
[18F]fluorine (t1/2 = 110 min).  Obtaining high radioactive yields is even more challenging 
for molecular imaging biomarkers labeled with other important positron emitting 
radioisotopes with shorter half-lives, such as 11C (t1/2 = 20 min) and 13N (t1/2 = 10 min). 
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Figure 2-1:  (A) Schematic representation of an integrated microfluidic device used in the production of 2-deoxy-2-
fluoro-d-glucose (FDG) (3a,b).  Three sequential processes—(i) concentration of dilute fluoride ion using a 
miniaturized anion-exchange column located in a square-shaped fluoride concentration loop, (ii) solvent exchange from 
water to dry MeCN, (iii) fluorination of the d-mannose triflate precursor 1, (iv) solvent exchange back to water, and (v) 
acidic hydrolysis of the fluorinated intermediate 2a (or 2b) in a ring-shaped reaction loop—produce nanogram levels of 
FDG (3a,b). The operation of the device is controlled by pneumatic valves, with their delegate responsibilities 
illustrated by their colors: red for regular valves (for isolation), yellow for pump valves (for fluidic metering 
circulation), and blue for sieve valves (for trapping anion exchange beads in the column module). (B) Optical 
micrograph of the device.  The various channels have been loaded with food dyes to help visualize the different 
components of the microfluidic chip: (red) control channels for regular valves, (blue) control channels for sieve valves, 
(yellow) control channels for pump valves, and (green) fluidic channels. 
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Ion Exchange Column for Fluoride Concentration 
The concentration of [18F]fluoride obtained from a proton-bombarded [18O]water is 
usually below 1 ppm, and performing fluorination reaction at such a low [18F]fluoride 
concentration is not feasible.  Because reaction volumes in microfluidic devices are on 
the level of nL, it would be advantageous if there were ways to concentrate desired 
reagents within the device to not only boost the overall production but also favor the 
reaction kinetics.  In addition, an ion exchange column can also be used for separation 
and purification of proteins, polypeptides, nucleic acids, polynucleotides, and other 
charged bio molecules, making it a versatile module to have in our chemical toolbox.    
 
Thus we sought to create a miniaturized anion exchange column (Figure 2-2) in the 
microfluidic device to concentrate the [18F]fluoride solution to ~ 100 ppm.   Sieve valves, 
developed by Carl Hansen and Joshua Marcus in our lab, (Figure 2-2 B) were created 
using a square-profiled fluidic channel and a thin control membrane.  Actuation of this 
membrane prohibits the passage of large particles while still permitting the solution to 
pass through the edges of the channel.  Anion exchange beads (Source 15Q, Amersham 
Biosciences) were packed into the column module by introducing an aqueous solution 
containing suspended beads into the microfluidic chamber.  The beads were activated by 
passing 1.0 M of KHCO3 through the column followed by sequential introduction of DI 
water (18 MΩ). 
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Figure 2-2: Schematic representations illustrate the operation mechanisms of (A) a regular valve having a round-
profiled fluidic channel and (B) a sieve valve having a rectangular-profiled fluidic channel.  When pressure is 
introduced into the control channels, the elastic membranes expand into the fluidic channels.  In a regular valve, the 
fluidic channel is completely sealed because of the perfect fit between the expended membranes and the round profile 
of the fluidic channel.  In a sieve valve, the square-profiled fluidic channel is only partially close, which allows fluid to 
flow through the two edges.  Sieve valves can be used to confine solid objects within the fluidic channel, but allow 
liquid to flow through it.  (C) Schematic illustration of the loading of anion exchange beads into a column module 
incorporating one fluidic channel and five sieve and five regular valves.  [□], open valve; [X], closed valve.  A 
suspended solution of anion exchange beads is introduced into the column modules where five sieve valves and five 
regular valves operate cooperatively to trap anion exchange beads inside the fluidic channel (total volume: 10 nL).  A 
miniaturized anion exchange column for fluoride concentration is achieved when the fluidic channel is fully loaded. (D) 
A snapshot of the bead-loading process in action 
 
Several iterations of concentration modules were constructed before a final design was 
settled upon.  A layout of the first-generation column is shown in Figure 2-3.  After the 
column is packed and activated, dilute fluoride solution fills the binding path and the 
eluting loop.  Pumps can then be turned to circulate the fluoride solution through the 
column for a preset amount of time.  After the binding of fluoride to the column is 
complete, the binding path is separated from the eluting loop by closing off valves.  
0.25M K2CO3 solution is introduced to the eluting loop and circulated until the fluoride 
ions are competed off the column.  The concentrated fluoride is then displaced and 
recovered from the device using DI water.   
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Figure 2-3: Layout of the 1st-generation anion exchange column.  Control channels (Red); Fluidic channels (Blue).  The 
column is designed to hold 25.7 ng of fluoride.  Dilute fluoride solution and K2CO3 solution are loaded from the left.  
Bead suspension, 1.0 M of KHCO3 and DI water are introduced from the top.  The green circular path in the center of 
the chip is the eluting loop.  The yellow serpentine channel to the top left and bottom left of the circle are part of the 
binding path.  The binding path holds 1.28 uL of solution, while the smaller eluting loop holds only 65 nL.   Maximum 
concentration factor is the ratio between volume of binding path and eluting loop or 19.7. 
 
Using the first-generation device, we measured the capacity of anion exchange column 
and compared it to our expected value.  A high concentration of fluoride solution (2000 
ppm) is flowed through the column to encourage complete binding.  An excess amount of 
DI water is then used to wash off unbound fluoride.   Thereafter, a 1M K2CO3 solution is 
then used to elute off the fluoride completely.  22.9 ng of fluoride ion is recovered when 
the column is designed to hold 25.7 ng (89.1% yield).  Dependence of amount of fluoride 
bound to the column to the number of times the dilute fluoride solution is passed through 
the column is also investigated.  It is found that increase in the number of times the dilute 
fluoride solution loops through the column only leads to a modest increase in amount of 
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fluoride bound to the column.  However, the loss of F18- through radioactive decay 
associated with the extended flow time offsets the gain in fluoride recovery.  
 
Figure 2-4:  Layout of the 2nd-generation anion exchange column.  Control channels (Red); Fluidic channels (Blue).  
The column is designed to hold 55.0 ng of fluoride.  Dilute fluoride solution and K2CO3 solution are loaded from the 
left.  Bead suspension, 1.0 M KHCO3 and DI water are introduced from the top.  The small rectangular path in the 
center of the chip is the eluting loop.  Metering pumps are incorporated at the inlets for precise metering of solutions. 
 
A layout of the 2nd-generation column is shown in Figure 2-4.  The binding path is 
completely taken out because the improvement in fluoride binding is minimal with 
multiple passing.  Pumps are added in the input line to gain improved control on the 
amount as well as the flow rate at which solutions can enter the anion exchange column 
(maximum flow rate of 160 nL/sec is achievable).  The size of the column is enlarged 
twofold to increase the binding capacity from 25.7 ng to 55 ng.  The size of the eluting 
loop is minimized (38.4 nL) to increase the concentration of fluoride competed off the 
column during elution. 
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Further testing was done using 5 ppm NaF as the dilute fluoride solution and 0.5 M 
K2CO3  as the eluting solution.  The results are summarized in Table 0-1.  The amount of 
fluoride loaded is controlled by the volume of dilute fluoride passing through the column.  
The optimum loading range for the anion exchange column as measured by percent 
recovery is between 60--90% of the total capacity.  An ultra dilute fluoride solution (0.2 
ppm) is used to see what factor of concentration is possible using the 2nd-generation 
column design.  29.4 ng fluoride is loaded onto the column (58% total capacity) and 13 
ng fluoride was recovered in final volume of 45 nL (285 ppm).  That is a greater than 
1400-fold increase in concentration. 
Table 0-1:  Efficiency of fluoride recovery over different loading range  
 Capacity Loaded 
(%) 
Amount of 
Fluoride Loaded 
(ng) 
Amount of 
Fluoride 
Recovered (ng) 
Efficiency of 
Recovery 
30  16.5 15.1 91.5% 
60  33.0 23.2 70.4% 
90  49.5 22.8 46.0% 
120  66.0 25.9 39.3% 
150  82.5 27.0 32.8% 
180  99.0 31.8 32.1% 
210  115.5 25.5 22.1% 
240  132.0 27.7 21.0% 
 
Reaction Loop for Solvent Exchange, Fluorination, and Acid Hydrolysis  
The challenges for conducting sequential chemical processes within microfluidic devices 
are (i) isolating distinct regions on the chip for individual chemical processes, (ii) 
accelerating diffusion-dominated mixing within an isolated microfluidic environment, 
and (iii) removing and exchanging solvents specific to each individual synthetic step.  
Elastomer-based microfluidic reactors (12,31) with integrated micromechanical valves 
provide elegant solutions to these challenges.  
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First, integrated valves (12) can isolate distinct regions on the device for distinct chemical 
processes, a capability that is virtually impossible to design into continuous flow 
microfluidic systems (7,32).  Second, a peristaltic pump, (12) comprised of  three 
adjacent valves in series, can be used to produce active mixing within a short fluidic loop.  
Continuous flow microfluidic devices, on the other hand, require long winding (33) or 
highly branched (34) channels to achieve efficient mixing between laminar flows.  This 
requires valuable chip real estate and flow time.  Third, the gas permeable PDMS matrix 
allows solvent exchange to occur within the microfluidic channel through direct 
evaporation, whereas glass- and silicon- based microfluidic devices have no intrinsic way 
to exchange solvents.  Finally, a solution inside a PDMS-based microfluidic reactor can 
be heated above its normal (atmospheric) boiling point.  This high-temperature and high-
pressure environment provides the conditions for accelerated rates of chemical processes.  
The pressure is not only controlled by the heat supplied to the chip, but it is also mediated 
by the porosity of the PDMS matrix. 
 
The reaction loop was designed to match the volume of concentrated fluoride solution 
from the eluting loop to maximize the fluoride concentration in subsequent steps.  
Because of the short path length of reaction loop, a peristaltic pump is used to enhance 
the mixing of reagents within the reactor.  Following the elution of fluoride, 20 nL of 
K2CO3 solution was introduced into the fluoride concentration loop to displace the 
concentrated fluoride solution into the reaction loop. The other 20 nL of volume is filled 
through a dead-end filling process (all the valves are closed except the valve controlling 
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the loading channel, the air inside the loop is pushed out through the porous PDMS 
matrix). 
Solvent Exchange 
With all the valves around the reaction loop closed, the device was heated on a digitally 
controlled hotplate with a gradient (100 oC for 30 seconds, 120 oC for 30 seconds, 135 oC 
for 3 minutes).  Due to the small thermal mass of the device, the heating is almost 
instantaneous.   Most of the water from the concentrated fluoride solution was removed 
through the first evaporation; however, a few droplets can be seen clinging to the reactor 
wall.   The device was then cooled down to 35 oC within 1 minute.  The limiting factor is 
the heating element rather than the device itself.  Anhydrous MeCN was introduced into 
the reaction loop through the bottom middle channel through dead-end filling.  This step 
took less than 20 seconds at 25 oC.  The device was heated again with a gradient (80 oC 
for 30 seconds, 100 oC for 1 minutes) to remove the remaining water inside the loop. It is 
found that if the temperature is ramped up too fast, there is a chance for pressure inside 
the chamber to exceed the valve closing pressure and cause the reactor to leak.  To 
prevent such a leakage, double valves are implemented around the reaction chamber and 
strict heating procedures are followed.   
Fluorination 
A 40 nL anhydrous MeCN solution containing 1,3,4,6-tetra-O-acetyl-2-O-
trifluoromethanesulfonyl-D-manno-pyranose (mannose triflate) (92 ng, 1.9 x 10-10 mol) 
and 4,7,13,16,21,24-hexaoxa-1,10-diazabicyclo [8,8,8]hexacosane (Kryptofix 222) (364 
ng, 9.6 x 10-10 mol) was introduced into the reaction loop containing the KF which was 
dried through the solvent exchange process mentioned in the previous section.  Direction 
22 
 
 
loading of concentrated KF solution is first used to establish the reaction parameter.  
Later KF concentrated from dilute fluoride solutions using the ion exchange column are 
also tested.  After all the valves around the reaction loop were closed, the reactor was 
heated at 100 oC for 30 seconds and maintained at 120 oC for 50 seconds. Meanwhile, the 
circulating pump was turned on to provide efficient mixing. After the chip was cooled 
down to 35 oC, the reaction residue inside the loop was flushed out with MeCN for GC-
MS analysis. Although we cannot obtain an accurate reaction yield from GC-MS analysis, 
it is obvious the entire peak for D-mannose triflate precursor disappeared after the 
reaction and the fluorinated intermediate was the only reaction product. (Figure 2-7 B) 
 
Figure 2-5:  Schematic diagrams summarize the fluorine substitution process which is composed of 3-step sequential 
operations in the microfludic device. (A) Kryptofix 222 / the mannose triflate 1 in anhydrous MeCN were introduced 
from the top middle channel to the reaction loop by dead-end filling. This step took 20 seconds at 25 oC.  (B) The 
reaction loop was heated with a gradient (100 oC/30 seconds, 120 oC/50 seconds).  At the same time, the solution was 
actively mixed by the circulating pump. The fluorinated intermediate 2a (or 2b) was obtained by the end of this step. (C) 
The reaction loop was cooled down to 35 oC within 40 seconds. 
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Acidic Hydrolysis 
After the fluorination step, 40 nL of HCl solution (3.0 N) was loaded into the reaction 
loop.  With all the valves closed and circulating pump running, the hydrolysis of the 
fluorinated intermediate was finished in 1 minute at a temperature of 60 oC.  After 
cooling down to 35 oC, the final product, [19F]FDG was flushed out from the reactor by 
water. The final aqueous solution was removed. Due to the low volatility, [19F]FDG was 
derivatized with TMSCl prior to GC-MS analysis. The GC-MS result indicated that the 
hydrolytic reaction of the intermediate results in [19F]FDG > 90% purity. (Figure 2-7 C) 
 
Figure 2-6:  Schematic diagrams summarize the hydrolytic process which is composed of 3-step sequential operations 
in the microfluidic device. (A) HCl aqueous solution (3.0 N) was introduced from the top right channel (in light blue) 
to the reaction loop by dead-end filling. This step took 20 seconds at 25 oC.  (B) The HCl and the fluorinated 
intermediate 2a (or 2b) were mixed by the circulating pump for 1 minute at 60 oC. In this step, the intermediate 2 (or 2b) 
was hydrolyzed to yield the final product FDG (3a,b). (C) The solution containing FDG (3a,b) (in dark blue) was 
flushed out of the device though the product line located at the bottom of the device. 
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Figure 2-7:  (A) GC-MS plot of a mixture containing MeCN, mannose triflate 1, and Kryptofix 222. The two peaks at 
retention times of 14.73 and 18.10 min correspond to mannose triflate 1 and Kryptofix, respectively.  (B) GC-MS plot 
of the mixture in (A) after its reaction with concentrated fluoride in the device.  The peak having a retention time of 
14.16 min corresponds the formation of the fluorinated intermediate 2b.  A calibrated integration of the chromatogram 
suggests a conversion yield of 95%. (C) GC-MS plot of a TMS-functionalized [19F]FDG (3b) which is obtained by 
treating crude [19F]FDG (3b) with TMSCl. The calibrated integration indicates that the hydrolytic reaction of 
intermediate 2b resulted [19F]FDG (3b) in > 90% purity. 
 
Cold 2-Deoxy-2-[19F]fluoro-D-glucose ([19F]FDG) Synthesis 
We performed a proof-of-concept trial using non-radioactive [19F]fluoride to test the 
feasibility of producing [19F]FDG within the device.  The acquired experimental 
parameters are employed directly for the production of radioactive [18F]FDG.  For the 
first process, concentration of dilute fluoride, a 5 ppm NaF solution was loaded into the 
anion exchange column.  The loading rate (5.0 nL/sec) was controlled using a metering 
pump.  After the fluoride solution was loaded completely, a K2CO3 solution (0.25 M, 18 
nL) was introduced to fill the rectangular loop.  The circulating pump module was then 
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turned on so that the K2CO3 solution (0.25 M, 18 nL) could loop through the column 
continuously to produce a concentrated KF solution.  Because the fluorination of the D-
mannose triflate requires anhydrous conditions, a digitally controlled hot plate was used 
to heat the device for removing water from the concentrated KF solution.  To completely 
extrude any remaining moisture, dry MeCN was loaded into the reaction loop and the 
device was heated again.  Moisture and MeCN vapor can penetrate and escape the gas-
permeable PDMS matrix.  Once the device had cooled to room temperature, an 
anhydrous MeCN solution (40 nL) containing the D-mannose triflate (92 ng, limiting 
reagent) and Kryptofix 222 (364 ng) was introduced into the ring-shaped reaction loop 
containing the dried KF.  This heterogeneous reaction mixture was mixed inside the loop 
using the circulating pump.  During this step, the device was heated (100 °C for 30 s and 
then 120 °C for 50 s) to yield the fluorinated intermediate, as analyzed by GC-MS.  This 
analysis indicated that the conversion yields for the fluorination process were 98%.  After 
removing MeCN by direct evaporation, 3 N HCl solution (40 nL) was injected into the 
device and the hydrolysis of the intermediate was conducted at 60 °C to obtain [19F]FDG, 
in > 90% purity, according to GC-MS analysis.  The PDMS materials were compatible 
(35) with MeCN and the entire synthesis was demonstrated on multiple chips.   
Hot 2-Deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) Synthesis  
720 μCi of [18F]fluoride in ca. 1 μL of [18O]water was introduced into the fluoride 
concentration loop of the device.  Because of the relatively high loading rate (65 nL/sec) 
as well as other competing anions present in the bombarded water, only 500 μCi of 
[18F]fluoride (ca. 3.3 x 10-11 mol, limiting reagent) was trapped in the column. An 18 nL 
of K2CO3 solution (0.25 M, 4.5x10-9 mole) was introduced to fill the rectangular loop, 
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and the circulating pump module was then turned on so that the K2CO3 solution could 
loop through the column continuously to produce a concentrated [18F]KF solution. After 
circulation, 20 nL of K2CO3 solution was introduced into the fluoride concentration loop 
to displace the concentrated [18F]fluoride solution into the ring-shaped reaction loop. 
With all the valves around reaction loop closed, the device was heated on a digitally 
controlled hotplate. The device was cooled down to 35 oC within 1 minute, and 
anhydrous MeCN (40 nL) was introduced into the reaction loop.  The device was heated 
again to remove the water residue inside the loop.  Kryptofix 222 (1.4 μg, 3.7 x 10-7 mol) 
and the mannose triflate (324 ng, 6.7 x 10-10 mol) in anhydrous MeCN were introduced 
into the reaction loop. The device was heated with a gradient (100 oC for 30 seconds, 120 
oC for 50 seconds). At the same time, the solution was actively mixed by the circulating 
pump to give [18F]fluorinated intermediate  in the device. After cooling the device down 
to 35 oC within 1 minute, HCl aqueous solution (3.0 N) was introduced into the reaction 
loop. The mixture was mixed by the circulating pump for 1 min at 60 oC. In this step, the 
intermediate was hydrolyzed to yield the final product [18F]FDG. After cooling down to 
room temperature, the final product, 190 μCi of [18F]FDG (ca. 1.25 x 10-11 mol, 38% 
yield) was flushed out from the chip by water for the analyses of radio-TLC and radio-
HPLC. The analyses of radio-TLC (Figure 2-8) and radio-HPLC suggested that the 
unpurified mixture obtained upon the sequential production of [18F]FDG has a 
radiochemical purity of 97.6 %.  Similar results were observed across multiple runs.  
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Figure 2-8:  Analytical TLC profile of the unpurified mixture obtained upon the sequential production of [18F]FDG (3a) 
in the first generation microfluidic device indicating that the radiochemical purity of the FDG production is up to 
97.3 %.  The two peaks with values for Rf of 0.0 and 0.4 correspond to [18F]fluoride and [18F]FDG (3a), respectively. 
 
2nd-Generation FDG Synthesizer 
A second-generation synthesizer was also designed with the capacity to synthesize larger 
[18F]FDG doses.  This chip has a coin-shaped reactor (5 μL volume) equipped with a 
vacuum vent. It was used to synthesize 1.74 mCi [18F]FDG sufficient for several mice 
experiments.  From the purified and sterilized product (Figure 2-10 A), two doses (375 
μCi and 272 μCi) were utilized for microPET- and microCT-based molecular imaging of 
two mouse models of cancer.  One of the mouse images is shown in Figure 2-10 B as a 2-
dimensional projection image.  This new design should ultimately be able to synthesize 
large quantities (i.e., 100 mCi) of [18F]FDG that is sufficient for several human PET 
scans.   
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Figure 2-9:  (A) A second-generation device is in action for the [18F]FDG (3a) production. (B) Schematic 
representation of the second-generation device composed of three major functional components, including (i) vent 
channel, (ii) coin-shaped reactor, and (iii) manifold for introduction of the mannose triflate 2a solution 
 
 
Figure 2-10:  (A) Analytical TLC profile of the unpurified mixture (blue curve) obtained upon the production of 
[18F]FDG (3a) in the second-generation device indicating that the radiochemical purity of the FDG production is up to 
96.2%. The two peaks have Rf values of 0.0 and 0.36 corresponding to [18F]fluoride and [18F]FDG (3a), respectively.  
After purification and sterilization, the [18F]FDG (3a) (black curve) with 99.3% radiochemical purity was employed 
for mouse microPET/microCT imaging.  (B)  Projection view of microPET/microCT image of a tumor-bearing mouse 
injected with [18F]FDG produced in a microfluidic chip. Organs visible are the bladder, kidneys, heart, tumor, and two 
lymph nodes. 
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Materials and Methods 
Fabrication of the First-Generation Device  
The chip was fabricated using the multi-layer soft lithography method. (12,36) Two 
different molds were first fabricated by photolithographic processes to create the fluidic 
channels and the control channels for actuating the values located in the respective layers 
of the PDMS-based device.  The mold used to create the fluidic channels was made by 
following a two-step photolithographic process. In the first step, a 45-μm-thick negative 
photoresist (SU8-2025) was spin coated on to a silicon wafer (Silicon Quest, San Jose, 
USA).  After UV exposure and development, a square-profiled pattern for the 
miniaturized anion exchange column was obtained.  In the next step, a second layer of 
45-μm-thick positive photoresist (AZ 100XT PLP) was then spin coated on the same 
wafer.  Prior to the UV exposure the mask was aligned (Karl Suss AmericaInc., 
Waterbury, VT) to ensure a good match between two sets of patterns of the control and 
fluid channels.  Once the positive photoresist was developed, the wafer was heated above 
the glass transition temperature of the positive photoresist.  As a result, the surface profile 
of the patterned positive photoresist was transformed into a round profile while the 
profile of the negative photoresist remained unchanged (square profile). This device has a 
channel height of 45 μm and width of 200 μm.  The control channels mold was made by 
introducing a 25-μm-thin negative photoresist (SU8-2025) pattern on a silicon wafer.  In 
order to achieve reliable performance of each valve, the width of the control channel was 
set at 250 μm in sections where the valve modules are located.   
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Before fabricating the device, both the fluidic and control molds were exposed to 
trimethylchlorosilane (TMSCl) vapor for 2--3 minutes.  A well-mixed PDMS (GE, RTV 
615 A and B in 5 to 1 ratio) was poured onto the fluidic mold located in a petri dish to 
give a 5-mm-thick fluidic layer.  Another portion of PDMS (GE, RTV 615 A and B in 
20:1 ratio) was spin-coated onto the control mold (1600 rpm, 60 s, ramp 15 s) to obtain 
the control layer.  The thick fluidic layer and thin control layer were cured in an 80 0C 
oven for 50 minutes.  After incubation, the thick fluidic layer was peeled off the mold, 
and holes were introduced onto the fluidic layer for access of reaction solutions.  The 
fluidic layer was then trimmed, cleaned, and aligned onto the thin control layer.  After 
baking at 80 oC for 60 minutes, the assembled layer was peeled off the control mold, and 
another set of holes were punched for access of control channels.  These assembled layers 
were then placed on top of a glass slide that was coated (1600 rpm, 60 s, ramp 15 s) with 
PDMS (GE RTV 615 A and B in 20:1 ratio) that had been cured for 45 minutes in the 
oven.  The device was done after overnight incubation. 
 
Control Interface   
The pneumatic control setup consists of 4 sets of eight-channel manifolds controlled 
through a BOB3 breakout controller board (Fluidigm, San Francisco, USA).  Argon gas 
that was pre-dried through a gas purifier (Hammond Drierit, Xenia, USA) provides 
pressure (30 psi) to the manifolds.  32 control lines from the device are individually 
connected to the corresponding channels on the manifolds with metal pins (23 Gauge, 
New England Small Pin Corp, USA) using Tygon microbore tubing (Cole-Parmer East, 
Bunker Court, USA).  When a channel on the manifold is activated, argon gas enters the 
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control line connected with the specific channel, providing pressure to close valves in the 
microfluidic device. The control interface was created using the Labview program on a 
PC.  A National Instruments card (AT-DIO-32HS) digitally controls the switching of 
manifolds through the BOB3 breakout controller board.  The Labview program allows 
for manual control of individual valves and for automation of the synthesis processes.   
 
Materials   
All reagents were purchased from Sigma-Aldrich.  Solvents purchased from VWR/EMD 
were purified according to literature procedure.  GC-MS was performed with GC/EI 
Time-of-Flight mass spectrometer (Micromass GCT). A DBS-MS capillary column (40 
m long, 320 μm of OD) was employed for GC analyses of [19]FDG intermediate and 
product using helium as carrier gas at flow rate of 1.2 mL/min. No-carrier-added 
[18F]fluoride (specific activity: > 10,000 Ci/mmol) was produced by 11 MeV proton 
bombardment of 95% 18O-enriched H2O via 18O(p,n)18F nuclear reaction using a RDS-
112 cyclotron. HPLC analysis was performed using a Rainin-HP system equipped with a 
γ-detector. A Phenomenex column (Econosphere-NH2, 5 μm, 250 × 4.6 mm) was used 
with a solvent system of 85% MeCN and 15% H2O.  Radio-TLC analysis was performed 
on silica plate (EM Separation Technology, Silica gel 60) with an eluent system of 85% 
MeCN and 15% H2O. 
 
Concluding Remarks 
Micro-reactors based upon integrated multilayer elastomeric microfluidics offer the 
potential for executing a sequence of chemical events, each carried out under different 
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solvent and/or physical conditions.  In addition, rates and yields of the chemical 
syntheses can be improved over standard procedures, and multiple distinct chemical 
syntheses can be executed on a single chip under fully automated and parallel operation.  
This technology enables acceleration of the synthetic process and the reduction of 
reagents and solvents required.  These integrated microfluidic chip platforms can be 
extended to other radiolabeled molecular imaging probes (37), and also to other chemical 
compounds produced by sequential synthetic processes.  This concept can be enabling of 
a number of applications, and the one specific application explored here is the preparation 
of biomarkers for PET-based molecular imaging.  Chips designed to produce both small 
animal and human-level doses of the common radiopharmaceutical, [18F]FDG were 
demonstrated, and both chip designs yielded enhanced operational efficiency and 
chemical economy. 
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Chapter 3  
SOLVENT RESISTANT ELASTOMERIC-BASED INTEGRATED MICROFLUIDICS: 
PROOF OF PRINCIPLE OLIGONUCLEOTIDE SYNTHESIS  
Introduction  
Synthetic chemistry presents numerous instances in which it would be useful to automate 
and miniaturize reactions.  Many synthesis problems require trial and error efforts in 
order to optimize yield. A miniaturized, automated chemical synthesizer would reduce 
manpower, reagent consumption, and cost.  Reducing reagent consumption for chemical 
synthesis also offers the possibility of reducing waste proportionately and is thus 
environmentally friendly. 
 
Microfluidic devices have shown great potential in realizing these goals (38).  However, 
because chemical synthesis requires the use of a wide variety of solvents, most 
microfluidic work in this area has been limited to continuous flow reactors fabricated in 
glass or silicon (39).  These platforms suffer from several disadvantages.  While simple 
manipulation of solvents and reactive species has been demonstrated in devices 
fabricated from hard materials, it remains difficult to scale up these devices to the levels 
of integration seen in recent elastomeric-based devices.  In addition, glass- and silicon- 
based microfluidic devices are often designed from scratch for each new application 
because of the lack of generality in the fabrication and fluid manipulation methods (40).  
Coupled with the exuberant cost in the fabrication of these devices, the application and 
commercialization of glass- and silicon- based microfluidics for fine chemical synthesis, 
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especially in the developmental stage where many iterations of designs need to take place, 
is still distant. 
 
In special cases where the solvents are mild, it has been possible to use integrated 
elastomeric micromechanical valves to perform batch synthesis at the nanogram scale of 
radiopharmaceuticals as demonstrated in the previous chapter.  Even though other 
impressive devices have been demonstrated, fundamental incompatibilities of PDMS 
with many solvents have limited this platform to applications involving only aqueous 
media (41,42).  Drawing inspiration from PDMS microfluidic device technology and the 
many qualities that have led to its success, our group has developed a novel technology 
based on a photocurable perfluoropolyether (PFPE) elastomer material.  Due to their 
elastomeric properties, these devices share many of the same advantages of PDMS 
devices with the added advantage that they are resistant to most solvents (43). 
 
The synthesis of oligonucleotide was chosen to demonstrate the capability of PFPE 
devices.  The recent boom in synthetic genes and long DNA construct has been fueled by 
a broad cross-section of applications within molecular biology, such as the design of 
genetic circuitry (44,45), the engineering of entire metabolic pathways for target 
molecule manufacturing (46), and the construction and re-engineering of viral and 
bacterial genomes (47,48).  While these applications require thousands or even hundreds 
of thousands of oligonucleotides, the amount of each sequence needed is actually very 
small.  For example, as little as a pico-mole of oligonucleotides are needed for successful 
gene assembly (49).  Commercially available synthesizers prepare DNA on a micromole 
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scale; this amount far exceeds what is needed.  Currently, oligonucleotides are available 
at a cost on the order of USD 0.1 per nucleotide.  This makes applications such as the de 
novo synthesis of bacterial genomes (106 bp in size) prohibitively costly, requiring on the 
order of USD 100,000 in oligonucleotides alone.  By scaling reactions down to volumes 
of less than a microliter, reagent costs can be substantially reduced.   
 
Also, the deblocking solution commonly used in phosphoaramidite chemistry contains 
dichloromethane (DCM).  DCM is a solvent that poses severe challenges with 
conventional elastomers such as PDMS (35). Microfluidic channels made in PDMS will 
swell and become clogged within seconds when exposed to DCM.  By choosing an 
application that requires repeated exposures to such solvent over its operation, we wish to 
demonstrate that PFPE is a viable choice of material for production of devices to be used 
in other organic syntheses as well.        
 
This chapter describes a microfluidic DNA oligonucleotide synthesizer (Figure 3-1) made 
of PFPE which performs reaction cycles adopted from the widely used phosphoramidite 
method (Figure 3-2). The device is capable of synthesizing 60 pmol of DNA 
oligonucleotides while consuming less than 500 nL of 0.1 mol/L phosphoramidite 
solution in each reaction cycle, thus filling in the void between the commercial 
synthesizers’ micromole scale and the sub-femtomole scale of the emergent microarray 
technology.  The reduction of reagent consumption is significant: a 60-fold reduction 
over conventional automation on a per sequence basis.  This approach demonstrates the 
usefulness of integrated micromechanical valves for complicated multi-step organic 
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synthetic reactions and enables automated chemical experiments with a wide variety of 
solvents. 
 
Figure 3-1:  Schematic of microfluidic oligonucleotides synthesizer.  The fluidic channels consist of both rounded and 
squared profiles.  The first eight channels are assigned to specific reagents: 1) acetonitrile, 2) deblocking reagent, 3) 
oxidizing reagent, 4) activator, 5) dT-CE phosphoramidite, 6) Pac-dA-CE phosphoramidite, 7) iPr-Pac-dG-CE 
phosphoramidite, and 8) Ac-dC-CE phosphoramidite.  The ninth channel serves two functions.  During experimental 
setup it is used as an inlet for silica beads.  During the experiment it is used as an outlet for unwanted reagents that are 
left in the main channel.  A solid-phase reaction column is formed in situ using partially closed column valves to trap 
the silica beads (5 μm in diameter). 
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Overview of Solid-Phase Oligonucleotide Synthesis 
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Figure 3-2:  The synthetic cycle of DNA oligonucleotides 
 
Almost all oligonucleotide synthesis is now done on a solid support, which allows for the 
elongation of the chain without intermediate purifications.  The 3′-OH group of the first 
nucleoside is attached to the solid support through a cleavable linker, and the synthesis 
proceeds by coupling the 5′-OH group of the growing chain to the 3′-phosphorus of the 
monomer being added.    
 
The synthesis is cyclical in nature and generally involves 4 steps with proper washing 
inbetween them.  Step 1 is deblocking.  The first base that is attached to the solid support 
has a DMT group protecting the 5’hydroxyl group, making it inactive.  DMT groups are 
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removed under acidic conditions.  By introducing 3% dichloroacetic acid (DCA) in 
dichloromethane (DCM), the 5’-hydroxyl group in the growing chain is now exposed.  
Step 2 is coupling.  The next base monomer cannot be added until it has been activated. 
This is achieved by adding tetrazole, a weak acid to the monomer. Tetrazole protonates 
the phosphoramidite nitrogen on the incoming base, leaving its 3'-hydroxyl susceptible to 
nucleophilic attack by the active 5'hydroxyl group of the preceding base. They then 
loosely bind to form an unstable phosphite linkage.    
 
Step 3 is capping.  During a coupling step, not all active 5’-hydroxyl sites of the previous 
base will form a phosphate linkage.  If this unreacted hydroxyl group is left alone, it is 
possible for it to react in a later coupling step. This would result in oligonucleotides with 
truncated sequences. To prevent this from occurring, the unbound, active 5’-hydroxyl 
group is capped with a protective group which subsequently prohibits that strand from 
growing again.  We have elected to leave out the capping step in our synthesis because 
we were satisfied with the purity of our oligonucleotides.  However, in Chapter 4 where 
longer sequences were made, a capping step is implemented to reduce the amount of 
truncated sequences.    
 
Step 4 is oxidation.  The phosphite linkage formed in the coupling step is unstable.  
Traditionally, a solution of dilute iodine in water, pyridine, and tetrahydrofuran is added 
to oxidize the phosphate trimester into a tetracoordinated phosphate.  However, we 
substituted iodine with (1S)-(+)-(10-Camphorsulfonyl)oxaziridine (CSO) (50), as the 
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oxidizing reagent because it allows the entire reaction cycle to carried out in anhydrous 
conditions.   
 
These steps are repeated until the desired sequences have been synthesized.  When the 
synthesis is completed, the chain must be cleaved from the support and the base and 
terminal 5′-OH-protecting groups removed. The final product is a mixture of full length 
and truncated oligonucleotides, cleaved protective groups, and ammonium ions from the 
final cleavage. Depending on the application, additional purification steps might be 
needed before the oligonucleotides can be put to use.   
Oligonucleotide Synthesis 
Preparation of Controlled Porous Glass Support  
The porous silica beads were modified with the first nucleoside (thymidine in our 
experiments) attached. We added 0.5 g of silica beads into 10 mL 8 mol/L HNO3, and 
refluxed it for 4 hours. The beads were washed with water and then dried in an oven at 
120 °C overnight. The dried beads were re-suspended into 10 mL anhydrous toluene and 
then 0.6 mL APTMS was added into the system. The mixture was refluxed for 24 hours 
and then filtered and washed with toluene and acetone. All beads were then transferred 
into a new vial with 75 mg 5’O-DMT-2’-dT-3’-O-succinate, 40 mg HATU, 100 μL 
DIEA, and 5 mL MeCN. The reaction vial was sealed and the mixture was stirred 
overnight at room temperature. Finally the beads were filtered, washed with MeCN and 
acetone, and then dried under vacuum.  We suspended the beads in MeCN and then 
packed the column as we described in Chapter 2.  
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Preparation of Reagents and Device 
All the phosphoramidite compounds were dissolved into anhydrous MeCN to form 0.1 
mol/L solutions. The CSO was dissolved in anhydrous MeCN (0.1 g/mL) and filtered 
through a 0.45 μm filter.  All the reagents were flushed through the microfluidic channels 
during setup to remove unwanted air bubbles.  Each synthesis cycle contained 3 reaction 
steps and 3 washing steps as described earlier (Figure 3-2). The total time of each 
synthetic cycle is 9 min.   
 
The coupling step requires two reagents, phosphoramidite and 5-ethylthio-1H-tetrazole, 
as activators. The two reagents were piped into the synthetic column in an alternating 
fashion (Figure 3-3): one reagent flowed continuously for 1.8 s then the other one flowed 
for 1.8 s. For the labeled oligonucleotides, we replaced one of the phosphoramidite 
solutions with Cy3-phosphoramidite and increased the coupling time to 5 min.  Final 
“DMT-off” (“MMT-off” for Cy3-phosphoramidite) was done by flowing deblocking 
reagent into the column for 2 min.   
 
After the MeCN wash, we released the “column valve” and flushed the beads out of the 
chip and into a micro-centrifuge tube. The MeCN was evaporated using centri-vap. We 
added 0.3 mL concentrated ammonium hydroxide into the tube and then incubated the 
tube at room temperature for 1 hour. The beads were spun down to the bottom of the tube 
by a centrifuge and then the liquid phase was transferred into a new tube and kept at 
room temperature for 3 hours for removal of the side-protection groups on the 
oligonucleotides.  Finally the tube was lyophilized to yield solid-form oligonucleotides. 
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Figure 3-3:  Schematic diagram of the coupling step. (A) Phosphoramidite is flowing through the column. (B) Activator 
is flowing through the column. 
Characterization of Synthesized DNA 
Electrophoresis 
The synthesized oligonucleotides were re-suspended into pH 7.5 TE buffer and mixed 
with a TBE-Urea sample loading buffer (Invitrogen). The samples (typical volume is 20 
μL) were loaded onto a TBE-Urea gel.  1X TBE running buffer (Invitrogen) was used.  
The temperature was set to ca. 60 ºC and the voltage was set to 175 V.  Usually a running 
time of 45 min to 1 hour was enough to achieve single-base resolution of the gel bands.  
For unlabeled samples, we used SYBR gold dye to stain the gels for 30 min.  A Typhoon 
9410 (GE Health) scanner was used to scan the gel images. The final images were 
processed using Matlab (Mathworks). 
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5’-Cy3-TTT TTT TTT TTT TTT TTT TT-3’ (Poly-dT 20-mer, Cy3 labeled) 
Synthesized poly(dT) DNA oligonucleotides (20 mer, with Cy3 labeled at the 5’-end) are 
compared to the standard sample purchased from IDT. The standard sample is a mixture 
of identical amounts of the HPLC purified poly(dT) 10-mer, 15-mer, and 20-mer. The gel 
image (Figure 3-4) indicates that the major product of our synthesis is the poly(dT) 20-
mer.  
 
Figure 3-4:  Lane 1 is the 5’-Cy3-labeled poly-dT 20-mer sample we synthesized from the PFPE microfluidic chip, 
without purification.  Lane 2 is the mixture of the HPLC purified Cy3-labelled poly-dT 10-mer, 15-mer, and 20-mer 
(all ordered from IDT) 
5’-CCG ACC TGG ATA CTG GCA TT-3’ (DNA 20-mer) 
We also synthesized the DNA 20-mer without fluorescent labels. We used both gel 
electrophoresis and LC/MS to test our product. Figure 3-5 is the gel image. Figure 3-6 
through Figure 3-9 are LC/MS data. The gel was stained with SYBR gold. Lane 2 
contains 1 pmol of DNA molecules, while lane 1 contains 10% of the product from a 
single reaction on the microfluidic chip. By comparing the fluorescent intensity of the 
bands, we can estimate that the total amount of the DNA oligonucleotides produced by 
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each run of the reaction is ca. 60 pmol. The reaction of the labeled DNA oligonucleotides 
has a similar yield.   
 
Figure 3-5:  Lane 1 is our synthesized unlabeled DNA 20-mer without purification.  Lane 2 is the HPLC purified 
unlabeled DNA 20-mer ordered from IDT   
Mass Spectrometry 
The synthesized oligonucleotides were sent to Novatia, LLC (Monmouth Junction, NJ) 
for HPLC/MS characterization. The LC column was a 2 × 50 mm Clarity C18 3 μm from 
Phenomenex and the experimental temperature was 40 °C. The gradient was 5--25% B in 
20 min at 200 μL/min. A = 0.075% hexafluoroisopropanol (HFIPA) / 0.0375% DIEA in 
water, B = 90% methanol with 0.075% HFIPA / 0.0375% DIEA. The MS data were 
acquired on an LTQ mass spectrometer from Thermo. The samples were analyzed by 
electrospray ionization (ESI) mass spectrometry. The detected signal was deconvoluted 
to generate the final mass spectra. 
Table 0-1: Chromatogram summary  
Retention Time (min) Base Peak Mass (Da) Intensity LC/MS Area Percent 
14.13 5475.4 1.61E+004 7.57 
14.53 5788.2 1.16E+005 24.64 
14.74 5803.3 1.92E+005 25.55 
14.96 6092.5 8.94E+005 42.24 
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From the deconvoluted mass spectra of product from various retention times of HPLC, 
one can conclude that the major impurities are DNA sequences with deletion of single 
nucleotides.  No obvious results were observed regarding material leached from 
fluoropolymers.  However, due to the inert nature of the fluoropolymer as well as 
complete curing of the device, leached material should have minimal or no effect on 
solid-phase synthesis of DNA.   
 
  
Figure 3-6:  LC/UV chromatogram of the synthesized DNA 20-mer at 260 nm 
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Figure 3-7:  The deconvoluted mass spectrum of the synthetic DNA 20-mer at the retention time of 14.96 min. The 
calculated molecular weight of the DNA 20-mer is 6093 and the detected molecular weight from MS is 6092.5.  The 
smaller peak with molecular weight of 5763.6 comes from a single deletion of nucleotide G in the expected sequence. 
 
Figure 3-8:  The deconvoluted mass spectrum of the synthetic DNA 20-mer at the retention time of 14.74 min. The two 
large peaks with molecular weight of 5779.0 and 5803.3 correspond to single deletions of nucleotide A or nucleotide C 
from the expected sequence, respectively. 
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Figure 3-9:  The deconvoluted mass spectrum of the synthetic DNA 20-mer at the retention time of 14.53 min. The 
large peak with molecular weight of 5788.2 corresponds to a single deletion of nucleotide T in the expected sequence. 
 
Melting Curve Measurement 
To further test that our synthesized oligonucleotides had the correct sequence, we 
measured the melting curve of the sample with complementary strands and 
oligonucleotides containing a single-base mismatch.   Our synthesized DNA was labeled 
at the 5’-end with Cy3-phosphoramidite. The two HPLC purified strands, complementary 
and single-mismatched, are purchased with FAM-labels at the 3’-ends.  When the two 
strands are hybridized, the fluorescent intensity of FAM is significantly reduced through 
FRET interaction between FAM and Cy3 fluorophores. When the temperature is elevated 
above the melting temperature, the two strands separate and the FAM signal recovers. By 
monitoring the fluorescent intensity of the FAM versus different temperatures, we 
measured the melting curve of the oligonucleotides (Figure 3-11). The measurement was 
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carried on a commercial microfluidic chip (Digital Isolation and Detection Chip, 
Fluidigm, South San Francisco, CA).  
 
1 pmol of standard DNA sample or the DNA sample synthesized from the microfluidic 
chips (same sequence, with 5’-Cy3 labeled, 5’-Cy3-CCG ACC TGG ATA CTG GCA 
TT-3’) and 1 pmol of FAM-labeled complementary strand (5’-AAT GCC AGT ATC 
CAG GTC GGT TT-FAM-3’) or 1 pmol of FAM-labeled single nucleotide mismatched 
strand (5’-AAT GCC AGT AAC CAG GTC GGT TT-FAM-3’) were mixed with Taq 
PCR buffer (doped with VOX dye for internal reference) to form 10 μL solutions. The 
complementary and single nucleotide mismatched strands had 3 extra Thymidine bases at 
the 3’-end because the fluorescent quantum efficiency would decrease drastically if the 
FAM was directly coupled to Guanosine. Negative control experiments (solutions 
containing only FAM-labeled samples or only Cy3-labeled samples, or none of the 
labeled samples) were also carried out on the same chip simultaneously. We heated the 
samples to 95 ºC for 5 min and then cooled them down to the room temperature to 
hybridize the DNA strands in the solutions.  
 
We loaded the samples into the chip by following manufacturer’s instructions. Each 
sample was delivered into 1200 isolated reaction cells (Figure 3-10). The chip was placed 
on a computer-controlled thermo-cycler and was excited by a band-filtered mercury lamp. 
The fluorescent signal was captured by CCD camera and both FAM and VOX channels 
were recorded. We cooled down the chip to 15 °C and then slowly increased the 
temperature from 15 ºC to 75 ºC. We captured the images while the chip was heated. The 
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VOX image at each temperature was used to correct for in-homogeneity of the excitation 
intensity over the chip area (~ 4 cm × 4 cm). The fluorescent signal for each sample 
integrated over ~ 250 individual cells was used for the data processing. Each intensity 
point was calibrated with a VOX channel signal, background-corrected with the negative 
control experiments, and then normalized. 
 
Compared with the standard samples, our synthesized oligonucleotides show similar 
melting temperatures but higher fluorescent intensity at lower temperatures, indicating 
that there is impurity in the product. This observation coincides with the results of 
electrophoresis and mass spectrometry. 
 
Figure 3-10:  The DID chip and a sample fluorescent image of the chip. Each bright square section in the fluorescent 
image indicates an isolated reaction well. 
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Figure 3-11:  Melting curve measurements of single strand (ss)-DNA 20-mer with complementary strand and 
oligonucleotides with a single mismatch, respectively. The four curves represent the mixture of standard purified ss-
DNA + purified complementary strands (?), standard purified ss-DNA + purified mismatched strands (?), unpurified 
synthesized ss-DNA + purified complementary strands (?), and unpurified synthesized ss-DNA + purified mismatched 
strands (?), respectively. 
Materials and Methods 
Synthesis of Perfluoropolyethers (PFPEs) 
In a typical synthesis, Fluorolink D4000 (1000 g, 0.24 mol) was added to a dry 2 L round 
bottom flask and purged with argon for 15 minutes. EIM (67.56 mL, 0.48 mmol) was 
then added via syringe along with Dichloropentafluoropentane (319 mL) and DBTDA (8 
mL). The solution was immersed in an oil bath and stirred at 50 oC for 24 h. The solution 
was then passed through a chromatographic column (silica, Dichloropentafluoropentane, 
5 × 5 cm). Evaporation of the solvent yielded clear, colorless, viscous oil (PFPE DMA) 
which was further purified by passage through a 0.22 μm polyethersulfone filter.  
 
In a typical cure, 1 wt% or 0.1% wt of DMPA (0.5 g or 0.05 g, 20.0 mmol or 2 mmol) 
was added to PFPE DMA (50 g, 12.0 mmol) along with 20 mL 
Dichloropentafluoropentane until a clear solution was formed. After removal of solvent, 
the viscous oil was passed through a 0.22 μm polyethersulfone filter to remove any 
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DMPA that did not disperse into the PFPE DMA. The filtered PFPE DMA was then 
irradiated with a UV source (Electrolite UV curing chamber model no. 81432-ELC-500, 
λ = 365 nm, with only one of the four lamps operating to produce 7 mW/cm2 power flux) 
while under an oxygen-free nitrogen purge. 
Fabrication of the Microfluidic Chips   
All the fabrication steps were conducted in a glove box purged with N2. The PFPE DMA 
was prepared with 2 different concentrations of photoinitiator, 0.1% and 1.0%. Before 
use, the polymer was bubbled with N2 for 30 min. A thick layer (2 mm) of PFPE DMA 
containing 0.1% of photoinitiator was poured onto the Si wafer having the desired flow 
pattern made of AZ50 (AZ Electronic materials) and SU-8 2025 features (only the 
reaction chamber for trapping beads). The thick layer was irradiated with a UV source 
(Electrolite UV curing chamber, ELC-500, λ = 365 nm, 7 mW/cm2) for 12 sec. Then 
PFPE DMA with 1.0% of photoinitiator was spin coated to a thickness of 30 µm (800 
rpm for 20 s) onto a Si wafer with the desired control pattern made of AZ50. This wafer 
was placed in the UV chamber and irradiated for 5 sec. The thick layer was removed, 
aligned to the thin layer and then irradiated for another 24 sec to bond them together. The 
chip was peeled off and taken out of the glove box to punch inlet and outlet holes, then it 
was placed back into the glove box.  A 40 µm thick layer of PFPE DMA with 1.0% 
photoinitiator was spin coated (600 rpm 20 s) onto a glass slide and then irradiated for 4 
sec. The chip was placed on top of the coated glass slide and then irradiated for 5 min. 
Operation of the Microfluidic Chips 
All the inlets and outlets of the chips are inserted with steel tubes (New England Small 
Tube Co., Litchfield, NH) and connected with either microbore PTFE tubing (for 
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chemical reagents) or Tygon tubing (for control valves). All the tubing is purchased from 
Cole-Parmer (Vernon Hills, IL). The valves are filled with Krytox oil. Both reagent 
delivery (10 psi) and valve actuation (30–40 psi) are pressured by argon. The pressure is 
switched on and off by computer-controlled solenoid valves (Pneumadyne, Plymouth, 
MN).  
Materials   
Porous silica beads (5 μm in diameters, pore size 200 nm) were purchased from Sepax 
Technology (Newark, DE). Fluorolink D4000 was purchased from Solvay Solexis 
(Thorofare, NJ). Dichloropentafluoropropane was purchased from SynQuest Laboratories 
(Alachua, FL). Isocyanatoethyl methacrylate (EIM, 95%) was purchased from Monomer-
Polymer & Dajac Labs (Feasterville, PA). 3-Aminopropyl-trimethoxysilane (APTMS), 
N,N-diisopropylethylamine (DIEA), (1S)-(+)-(10-camphorsulfonyl)oxaziridine (CSO), 
anhydrous toluene, 2,2-Dimethoxy-2-phenyl acetophenone (DMPA, 99%), and 
Dibutyltin diacetate (DBTDA, 99%) were purchased from Aldrich (Milwaukee, WI). 5-
Ethylthio-1H-tetrazole (activator, 0.25 mol/L solution in anhydrous acetonitrile), 
deblocking mix (3% dichloroacetic acid (DCA) in dichloromethane (DCM)), anhydrous 
acetonitrile (MeCN), 5’-dimethoxytrityl-N-phenoxyacetyl-2’-deoxyAdenosine-3’-[(2-
cyanoethyl)-(n,N-diisopropyl)]-phosphoramidite (Pac-dA-CE phosphoramidite), 5’-
dimethoxytrityl-N-acetyl-2’-deoxyCytidine-3’-[(2-cyanoethyl)-(N,N-diisopropyl)]-
phosphoramidite (Ac-dC-CE phosphoramidite), 5’-dimethoxytrityl-N-p-isopropyl-
phenoxyacetyl-deoxyGuanosine-3’-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite 
(iPr-Pac-dG-CE phosphoramidite), 5’-dimethoxytrityl-2’-deoxyThymidine-3’-[(2-
cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite (dT-CE phosphoramidite), and 1-[3-(4-
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monomethoxytrityloxy)propyl]-1’-[3-[(2-cyanoethyl)-(N,N-
diisopropyl)phosphoramidityl]propyl]-3,3,3’,3’-tetramethylindocarbocyanine chloride 
(Cy3-phosphoramidite) were purchased from Glen Research (Sterling, VA). 5’-O-(4,4’-
dimethoxytrityl)-thymidine-3’-O-succinic acid (5’O-DMT-2’-dT-3’-O-succinate) was 
purchased from Monomer Science, Inc. (New Market, AL). 2-(7-Aza-1H-benzotriazole-
1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU) was purchased from 
Anaspec (San Jose, CA). SYBR Gold nucleic acid gel stain, pre-cast 15% TBE-Urea 
denaturing polyacrylamide gels (1.0 mm, 10 well), and ultrapure water were purchased 
form Invitrogen (Carlsbad, CA). Tris-EDTA (TE) buffer (pH 7.5) was purchased from 
Integrated DNA Technologies (IDT, Coralville, IA). All the DNA oligonucleotides, 
except the ones we synthesized from the microfluidic chips, were ordered from IDT and 
HPLC purified. 
Concluding Remarks  
In conclusion, we have demonstrated that microfluidics can be used for batch synthesis of 
DNA using phosphoramidite reagents and conventional solvents.  We envision a number 
of direct applications, in spite of the fact that only picomoles of products are produced.  
First, DNA is special in that it can be biochemically amplified and it has been shown that 
one can perform whole gene synthesis with as little as femtomoles of the source 
oligonucleotides (49).  Second, if the assay is to be performed on the chip, it is possible to 
elute the product DNA in nanoliter volumes, thus creating concentrations that are 
comparable to what are used on the benchtops.  This may be useful, for example, in 
screening siRNA sequences (51), creating DNA nanostructures (52), and for DNA 
computing (53,54)  
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Chapter 4  
PDMS-BASED PARALLEL MICROFLUIDICS OLIGONUCLEOTIDE 
SYNTHESIZER: OPENING TO HIGH-THROUGHPUT SYNTHESIS 
APPLICATIONS 
Introduction  
De novo gene synthesis is a powerful tool that can be used in a broad cross section of 
applications, including the study of large sets of genes, the design of genetic circuitry, 
and the engineering of metabolic pathways for the production of small molecules.  The 
basic concept of de novo gene synthesis involves taking a pool of short oligonucleotides 
and assembling them into larger constructs using some form of polymerase chain 
assembly or approach involving ligase chain reactions (55,56). 
 
The source of these short oligonucleotides has remained relatively unchanged for the past 
twenty years.  Traditional methods of solid-phase oligonucleotide synthesis (21,22), 
where each oligonucleotide is synthesized individually on a separate column or in a 
multi-well plate, produce high yields but are costly. For the assembly of long genes or 
even whole genomic sequences, the cost of the starting oligonucleotides alone is 
prohibitive for most applications in academia, as discussed in Chapter 3.  Smaller-scale 
synthesis strategies are needed to bring down the cost of starting oligonucleotides before 
de novo gene synthesis can be widely adopted. 
 
The development of optical and electro-chemical deprotection strategies heralded a new 
era of parallel oligonucleotide synthesis methods.  These technologies have led to a 
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number of commercially available DNA microarrays (57).  Depending on the chip 
platform being used, several thousand to several hundred thousand distinct 
oligonucleotides can be synthesized on a single chip.  In principle, these massive parallel 
microarrays can reduce the cost of oligonucleotides by several orders of magnitude.    
 
Despite these promising advancements, there are still several problems inherent in 
microarray technologies which hinder their direct adaptation to synthesizing 
oligonucleotides for gene assembly.  Because of their small feature size and flat reaction 
surface, current microchips produce very small amounts of oligonucleotides (107--108 
molecules per sequence) (11).  Such low yields of oligonucleotides are insufficient to 
drive a gene assembly reaction.  To overcome this problem, the oligonucleotides can be 
designed with two flanking adapter sequences and amplified by PCR.  These adapter 
sequences are then removed using a type II restriction enzyme after amplification, 
making the effective length of the oligonucleotides used in the gene assembly process 30-
-40 nucleotides shorter than what is synthesized on the microarray (24).   
 
Another problem associated with microarray synthesis technology is that all the 
oligonucleotides must be cleaved off the chip as a single mixture.  While the ability to 
synthesize thousands or even hundreds of thousands of oligonucleotides on a single chip 
is beneficial, the sheer number of different strands synthesized on a chip requires careful 
planning to handle the complexity of all the possible interactions from the various 
sequences in the mixture (49).  
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The oligonucleotides obtained from microarray technologies are also of a lower quality 
compared to those produced with existing solid-phase strategies due to a deblocking step 
which is less efficient.  While many advances have been made since the use of the photo-
cleavable protection group 5’-(α-methyl-6-nitropiperonyl-oxycarbonyl), or “MeNPOC”, 
which was first proposed by Fodor (58), the average stepwise efficiency of synthesis 
from new PGA (photogenerated acid) systems still only approaches ~ 97% (23) 
compared to the 99.5% stepwise yield cited by Integrated DNA Technologies using 
conventional solid-phase technology.  At these efficiencies, the yield of full-length 30-
mer product (compared to truncated sequences) falls from 86% for solid-phase methods 
to 40% for microarray-based methods.  For the longer 50—60-mer nucleotides with 
adapters synthesized on the microarray the yield is even lower, resulting in synthesis 
impurities which become a significant concern.  An ink-jet oligonucleotide synthesizer, 
which uses conventional solid-phase chemistry, fares better with a step-wise efficiency 
between 96.7% to 98.8% (59,60).  However, as this method also uses planar substrates, 
longer sequences still need adapters to allow amplification before use. 
 
This chapter describes a programmable microfluidic synthesis platform made of PDMS 
that addresses many of the limitations inherent to current microarray DNA synthesis 
technologies.  This device is capable of synthesizing ~ 100 pmol of an oligonucleotide 
sequence per column while consuming less than 250 nL of 0.1 M phosphoramidite 
solution per column in each reaction cycle.  This is a twofold reduction in reagent 
consumption coupled with a twofold increase in products when compared to the PFPE 
microfluidic synthesizer in Chapter 3.  As a proof of principle, we synthesized 16 
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oligonucleotides on a single device; without further purification, we successfully used 
these sequences to assemble a DNA construct approximately 200 bp long.  This 
microfluidic platform can potentially reduce the cost of DNA synthesis for gene assembly 
and enable greater accessibility of this methodology in research.  The microfluidic 
architecture with integrated valves also provides a means to individually manipulate and 
collect products from each column.  Sets of oligonucleotides with potentially disruptive 
interactions can be separated into different pools to avoid problems in gene assembly.  
Furthermore, this platform lends itself to further integration with other processes 
including gene assembly, cloning, or purification on chip (49,61,62). 
Microfluidic Oligonucleotide Synthesizer 
The PDMS-based parallel microfuidic DNA synthesizer, shown in Figure 4-1, was 
fabricated using a standard multilayer soft lithography (MSL) method (12,63).  PDMS is 
advantageous over other materials such as PFPE as it is readily available and 
straightforward to use in fabrication, thus allowing the manufacturing of devices that are 
much more complex than our single reactor chemical DNA synthesizer (64).  The device 
can be roughly divided into three components.   
 
The front component handles all the reagents and has remained mostly unchanged 
compared to the previous microfluidic DNA synthesizer made of PFPE.  In each 
synthesis step, the valve for the desired reagent opens while others remain closed, 
delivering the appropriate reagent by means of back pressure.   
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The middle component consists of a binary tree which produces a uniform flow rate 
across all reaction columns.  Squared profile channels are used in the construction of 
binary tree because flow velocity is much more constant across the width of a square 
channel compared to the parabolic velocity profile associated with a rounded channel.  
The herringbone topology within the binary tree facilitates proper mixing of reagents.  
The total volume of the binary tree is 1.49 µL.   
 
The end component consists of a sixteen nanoliter-scale reaction chamber array as 
illustrated in Figure 4-1B.  Smaller, more compact reaction columns are also possible 
using the same fabrication method.  The column array was designed to allow parallel 
loading of solid supports.  Purge lines were implemented to avoid cross contamination 
between synthesis steps by properly purging residual reagent within the binary tree.  Each 
reaction column measures 4500 µm long, 200 µm wide, and 30 µm high to give a column 
volume of 27 nL.  The 100 pmole synthesis scale is chosen to achieve sufficient product 
yields for several ligation assembly reactions after standard analysis methods.  Additional 
sieve valves (denoted as compression valves) were added to the middle of the columns to 
prevent rearrangement of closely packed spherical beads when a pressure drop occurs 
between synthesis steps, minimizing bead loss.  Over 95% of resin was retained after 40 
cycles (20 hr) of synthesis. 
 
During operation, appropriate reagents are driven by pressure into binary trees that 
precede the reaction columns.  Each reaction column is gated by an individually 
addressable valve that not only controls which phosphoramidite solution enters the 
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column but also allows varied exposure time of solutions to that column, if necessary. 
Because each reaction column is physically separated from the others, the reaction cross-
talk between adjacent columns is minimized.  While contamination is possible between 
synthesis steps when residual reagents enter the reactors, the problem is eliminated by 
adequate flushing of the binary tree after each step.  In addition, by physically separating 
the columns, the contents of each column can be selectively eluted.  This is unlike 
microarray technologies in which all the products are cleaved off into a single mixture. 
 
 
Figure 4-1:  (A) Schematic diagram of a 16 column microfluidic DNA synthesizer.  The control lines are shown in red, 
the fluidic lines in blue, the herringbone mixers in yellow, and the square profiled binary tree and reactor columns in 
green.  (B) Close-up schematic of the column array. The red and yellow valves close fully when activated; the blue and 
green valves are sieve valves that allow fluid flow while trapping CPG beads.  The column flush valves open and close 
in unison to allow residual reagent in the binary tree to be washed away between steps to avoid contamination.  The 
addressable inlet valve controls which columns the reagents enter.  The compression valves prevent rearrangement of 
closely packed spherical beads when a pressure drop occurs between steps. 
Microfluidic Oligonucleotide Synthesis 
The synthesis method carried out in the PDMS-based device is similar to the standard 
phosphoramidite chemistry (21,22) described in Chapter 3.  However, the standard 
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solution of 3% dichloroacetic acid in dichloromethane used during the normal deblocking 
step was replaced by 10% trifluoroacetic acid in acetonitrile to ensure solvent 
compatibility with PDMS.  Also, oligonucleotide synthesis starts on universal linker-
derivatized control porous glass beads (65), thus the 1st nucleotides no longer have to be 
coupled to the CPG beforehand.    
 
Short oligonucleotides approximately 15--25 nucleotides in length can be synthesized 
without any capping step.  Oligonucleotides greater than 40 nucleotides in length 
required capping steps to achieve high yield of full-length product.  Each synthesis cycle 
contained 7 reaction steps and 4 washing steps. The step-sequence and times are as 
follows here: deblocking (1.8 min), washing (4 min), coupling T (2.5 min), coupling G 
(2.5 min), coupling A (2.5 min), coupling C (2.5 min), washing (1 min), capping (2.5 
min), washing (2 min), oxidizing (2 min), washing (2 min).   
 
An extended deblocking condition of 2.5 min instead of the normal 1.8 min was used for 
the initial removal of the DMT group from the secondary hydroxyl group of the universal 
linker.  The initial coupling step to the universal linker was run for 3 min instead of the 
normal 2.5 min.  During the coupling step, the two coupling reagents (phosphoramidite 
and activator) were sent through the reaction columns alternately, with one reagent 
flowing continuously for 0.27 s followed by the other for 0.27 s before cycling.  The final 
deblocking of the finished oligonucleotides was done by flowing deblocking reagent into 
reaction columns for 2 min.  After an extended acetonitrile wash, we released the 
“column valves” and flushed the beads out of the chip and into micro-centrifuge tubes. 
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The acetonitrile was evaporated using centri-vap. In the final cleavage step, 75 µL 
concentrated ammonium hydroxide was added into the tubes and then incubated at 55 ºC 
for 12 h. The beads were centrifuged and then the liquid phase was transferred into new 
tubes and lyophilized to yield oligonucleotides as pellets. 
Modeling of Oligonucleotide Synthesis  
A simple computational model is developed to predict the length distribution of product 
oligonucleotides to better understand how each chemical step affects the overall yield.  
The three reaction steps taken into consideration are deblocking, coupling, and capping.  
The effects of depurination or consecutive couplings that would give longer products are 
not considered.  The efficiencies of each reaction step are assumed to be constant 
throughout the entire synthesis reaction.   
 
Three species are tracked in the model: oligonucleotides with free OH groups (FREE), 
oligonucleotides with the DMT group attached (DMT), and oligonucleotides that have 
been capped (CAPPED).  
 
 
The oligonucleotide can be predicted by iteration of the following equations:  
 
DMTj+1(n) = DMTj(n)*(1-deblockeff) + DMTj(n-1)*deblockeff*coupleeff  
  + FREEj (n-1)*coupleeff  
 
FREEj+1 (n) = [FREEj (n)+ DMTj (n)*deblockeff]*(1-coupleeff)*(1-capeff) 
 
CAPPEDj+1(n) = CAPPEDj (n) + FREEj (n)*(1-coupleeff)*capeff  
  + DMTj (n)*deblockeff*(1-coupleeff)*capeff  
 
where n = the length of the nucleotide and i = the cycle number in the synthesis reactions.  
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At the start of the synthesis, only protected universal linkers are present inside the 
reaction column, which correspond to oligonucleotide length of 0.  The initial condition 
is therefore DMT(0) = 1, FREE (0) = 0, and  CAPPED (0) = 0. 
 
In the first synthesis cycle, the products from the deprotection step are  
 
DMT(0)  = 1-deblockeff 
FREE(0) = deblockeff 
 
The free hydroxyl groups from the universal linkers are allowed to react in the coupling 
reaction.  DMT(1) = deblockeff * coupleeff. Those hydroxyl groups that did not react 
remain as FREE(0) =  deblockeff*(1-coupleeff). 
 
Capping only affects the free hydroxyl groups remaining.  Thus, after the capping step, 
we have CAPPED(0) =  deblockeff*(1-couple eff)*capeff, and  free hydroxyl group 
remaining in the system is further reduced to FREE(0) = deblockeff*(1-coupleeff)*(1-
capeff). 
 
At the end of the first synthesis cycle the species in our system are: 
DMT1(0) = 1-deblockeff  DMT1 (1) = deblockeff * coupleeff 
FREE1(0) = deblockeff*(1-coupleeff) )*(1-capeff) 
CAP1(0) = deblockeff*(1-coupleeff)*capeff 
 
 
To predict the distribution of different species at the end of two cycles, one only has to 
repeat the analysis using the end product distribution of cycle one as the initial condition.  
We simulated a synthesis length of 40, which is longer than what is needed for most 
applications.  Graphs for a few tested parameters are shown below: 
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Figure 4-2:  The product distribution of oligonucleotides predicted by the model.  (A) High yield synthesis conditions 
(without capping) with coupling and deblocking efficiency of 99%.  The major product is the full length 
oligonucleotide.  (B) Same high yield conditions as in A, now with capping at an efficiency of 99%.  The total yield on 
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the full length product does not change between the two cases; however, the amount of truncated product (N-1 mer) is 
reduced.  (C) Low yield synthesis conditions (without capping) with coupling efficiency of 99% and deblocking 
efficiency of 98%.  The major product is the truncated sequence (N-1 mer).  (D) Low yield synthesis conditions with an 
additional capping efficiency of 99%.  The additional capping step successfully reduces N-1 mer and the full length 
oligonucleotide is once again the full length product.    
 
The differences in the qualities of oligonucleotides synthesized with and without capping 
are compared using our model, with different values for the reaction parameters sampled 
to reveal the effect of individual reaction steps.  The metric chosen to evaluate the 
qualities of the synthesized oligonucleotides is the ratio between the full length product N 
mers and N-1-mers.  The reason this metric is chosen is that it is very difficult to 
discriminate between the N-1-mers and N-mers by either physical separation or other 
biochemical means.  While much shorter truncated sequences will not participate further 
in gene assembly reactions because they would be less likely to anneal properly at the set 
temperature, N-1-mers behave very similarly to the full length product and could be 
incorporated in the ligation reaction. 
 
The results from the different modeling parameters are summarized in Table 0-1 and 
Table 0-2.  The numbers given in the table are the ratio of full length product (N-mer) to 
products with a single deletion (N-1-mers).  The capping efficiency is set to 0.99 for the 
capped system and 0 for system without capping.       
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Table 0-1  Summary of oligonucleotide synthesis using different parameters in a model system without capping.  The 
metric is the ratio of full length product (N mer) to side product with a single deletion (N -1 mer)  
Without Capping  Deblock Efficiency  
0.995  0.99  0.98  0.97  
Coupling  
Efficiency  
0.995  2.475  1.642 0.975 0.690 
0.99  1.642 1.225  0.809 0.600 
0.98  0.975 0.809  0.600 0.475 
0.97  0.690 0.600 0.475 0.392 
 
Table 0-2  Summary of oligonucleotide synthesis using different parameters in a model system with capping.  The 
metric is the ratio of full length product (N mer) to side product with a single deletion (N -1 mer) 
With Capping  Deblock Efficiency  
0.995  0.99  0.98  0.97  
Coupling  
Efficiency  
0.995  4.926 2.457 1.217 0.804 
0.99  4.829 2.426 1.207 0.798 
0.98  4.514 2.332 1.177 0.782 
0.97  4.090 2.203 1.137 0.761 
 
In synthesis without capping steps, the ratios of N-mer compared to N-1-mer forms a 
square matrix.  The deblocking efficiency is just as important as the coupling efficiency. 
However, if a capping step is introduced to the synthesis cycle, the coupling efficiency 
becomes less crucial to synthesizing high quality oligonucleotides because the capping 
step is able to remove truncated species with free hydroxyl groups and prevent them from 
being elongated further.  This essentially removes oligonucleotides that have failed to 
couple from going further.  However, if the truncated species still has the protecting 
group attached due to poor deblocking, the capping step has no effect. 
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As the Table 0-2 reflects, in a system with capping, given a set deblocking efficiency, the 
ratio of N-mer to N-1-mer does not change as much even if the coupling efficiency is 
reduced by 2%.  However, given a set coupling efficiency, if the deblocking efficiency 
were to drop by 2%, the ratio is reduced by more than 5-fold.  Thus, efficient deblocking 
is very crucial to making high quality oligonucleotides, even in a system with capping.      
Development of Novel Deblocking Solution Compatible with PDMS 
By switching to a PDMS-based device for the ease of fabrication, we once again have to 
address the issue of limited solvent compatibility.  In traditional phosphoramidite 
chemistry, deblocking solution consists of 3% dichloroacetic acid (DCA) in 
dichloromethane (DCM).  However, DCM is incompatible with PDMS and leads to 
swelling and possible delamination of multilayer devices (35).  There are two logical 
substitutes that have shown to work well with PDMS: acetonitrile and water.   Each, 
however, has its own drawbacks.   
 
While traces of water are used in conjunction with iodine and pyridine in the oxidative 
step of synthesis, its presence can greatly hamper the efficiency of the coupling step.  
From our previous work, we found that by switching from the traditional oxidative 
solution which contains water to CSO in acetonitrile, the purity of our oligonucleotides 
improved dramatically.  We attributed this to the residual water that had not been 
removed completely from the reaction columns between washing steps.  This problem 
can potentially be addressed by extending the washing step with anhydrous acetonitrile 
between the deblocking step and the coupling step.    
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Acetonitrile is a mild solvent that is already used in the coupling and washing step of 
traditional oligonucleotide synthesis.  However, the active acid traditionally used for 
deblocking (DCA) forms a complex with acetonitrile that drastically slows detritylations 
(66).  Therefore, if one were to use acetonitrile in the deblocking step, a novel deblocking 
solution using a different acid or concentration must be formulated.   
 
Heterogeneous phase detritylation processes are complex with many chromatography 
effects, such as the retardation of detritylation due to acid binding with the 
oligonucleotides and the recapture of free DMT cation by 5’-OH group. In addition, the 
interplay of incomplete deblocking and losses of oligonucleotide bases due to 
depurination make rigorous kinetic modeling and analysis difficult.  We adopted a 
practical approach of analyzing the end product of the synthesis and using the ratio of 
full-length product to truncated byproducts as a benchmark to evaluate the success of the 
deblocking step. 
 
Aqueous Deblocking  Solution  
Moocroft et al. (67) have successfully demonstrated a system in which oligonucleotides 
are synthesized on linker derivatized on planar PDMS surfaces using 10% trifluoroacetic 
acid (TFA) in aqueous solution as deblocking agent.  We attempted to apply their 
deblocking strategy for our device.  The monitoring of detritylation in aqueous solution is 
much more difficult than in DCM because the characteristic orange color caused by trityl 
cations is quickly quenched.  A rough estimate of deblocking time cannot be made by 
visual inspection, thus a long deblocking time of 4 min is chosen to ensure detritylation is 
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driven to completion.  Synthesis of the homopolymers A20, G20, C20, and T20 are carried 
out.   
 
Figure 4-3:  Polyacrylamide gel electrophoresis of different homopolymers with length of 20 bases using 10%TFA in 
aqueous solution as deblocking solution.  L denotes a ladder that is 20 nucleotides in length.  Both A20 and G20 samples 
contain no full length product due to poor coupling as well as depurination.  T20 lanes contain some full length product 
but with oligonucleotides which are mostly truncated, indicating poor coupling efficiency.  
 
Gel electrophoresis of the products in Figure 4-3 shows that no full length materials are 
observed in lanes for A20 and G20.  While the T20 lane does exhibit full length 
oligonucleotides, the majority of products are truncated sequences.  No products are 
observed for C20 because of inefficient staining homopolymer of cystine using SYBR 
Gold (68).  Because homopolymers of purines (A20 and G20) are of a much lower quality 
compared to homopolymers of pyrimidines (T20), the time of exposure to deblocking 
solution may have been excessively long and allowed extensive depurination to take 
place.  Assuming that deblocking is indeed complete, the poor synthesis of T20 can be 
attributed to insufficient coupling.  Extending washing time of anhydrous acetonitrile 
from 2 min to 4 min did not result in improved yield.  These experiments showed that 
keeping the entire synthesis process water-free would result in better yield as well as 
require less time.  Hence, the pursuit of an aqueous deblocking solution was abandoned.             
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Deblocking Solution Based in Acetonitrile    
We then broadly surveyed several deblocking solutions composed of different organic 
acids in acetonitrile during the synthesis of the homopolymer A20.  Adenine was chosen 
because it is the base most sensitive to depurination (69).  We found that trifluoroacetic 
acid was most suitable (Figure 4-4).  Initially, we established that 5% TFA in acetonitrile 
with a deblocking time of 2.0 minutes was sufficient for synthesis of short 
oligonucleotides.  However, in experiments where long oligonucleotides (longer than 35-
mers) were synthesized, we observed that the orange color of DMT cation persists well 
over the 2.0 min deblocking time at later synthesis cycles.  We believe that acid binding 
to the growing oligonucleotide depletes free acid from the deblocking solution at higher 
oligonucleotide mass densities due to the increased length.  We addressed this problem 
by increasing the deblocking acid concentration to 10%.  The use of higher acid 
concentration allows quicker saturation and gives faster and more complete detritylation.  
Additional experiments were performed using 10% TFA in acetonitrile in the synthesis of 
homopolymer A40 with capping.   The deblocking time was varied at 30 second intervals 
from 0 to 3.5 minutes; the optimum deblocking time was found to be between 1 min and 
2 min (Table 0-3).  At longer deblocking times, losses of full-length nucleotide product 
through depurination exceeded gains from increased deblocking efficiency. 
70 
 
 
 
Figure 4-4 Effect of different deblocking acids and deblocking time on the quality of A20 homopolymer.  A selection of 
organic acids is broadly surveyed as candidates to be used in a acetonitrile based deblocking solution.  5% TFA is 
found to be most suitable with a optimal deblocking time between 2 min and 2.5 min.    
 
Table 0-3: Effect of deblocking time on the quality of A40 homopolymer using 10% TFA in acetonitrile.  A minimum of 
1 min deblocking time is needed for successful deblock.  The quality of the homopolymer starts to drop with 
deblocking time above 2.5 min.  This suggests that the increased deblocking efficiency at longer times are offset by 
losses of full-length product through depurination.   
  0 sec  30 sec  1 min   1.5min  2.0min  2.5min  3.0min  3.5min 
N  0  0.351  0.671  0.651  0.656  0.644  0.644  0.598 
N‐1  0  0.284  0.329  0.349  0.344  0.356  0.356  0.402 
N‐2  0  0.214             
N‐3  0  0.151             
 
Construction of Gene Fragment from Bacillus Cereus 
A gene fragment from Bacillus cereus was selected for synthesis through a ligation 
mediated assembly method.  Oligonucleotide sequences were derived from a custom-
developed program that first divides the sequence into oligonucleotides with a desired 
melting temperature range while keeping track of the melting temperature variation 
between the pieces.  The set of pieces with the least variation in melting temperature was 
chosen.  The program then generated the sequence of the sense strand by stitching every 
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two pieces together, and the anti-sense strand using the same method but with an offset of 
a single piece.  A summary of the oligonucleotide set is provided in Table 0-4.  
Table 0-4:  Oligonucleotide sequences used for the ligation-mediated assembly of a gene fragment of Bacillus cereus.  
The similar starting sequences of F3 and F9 that led to side products during the assembly are highlighted in red. 
 Forward Sequence  Reverse Sequence 
F1 GTATACTTCCAATCCAATGCA R1 TCGCTTTCATTGCATTGGAT 
F2 ATGAAAGCGAAGAAAAAAGATAAA R2 ATATTCAGAAGTTTTATCTTTTTTCT 
F3 ACTTCTGAATATCAGTACGTTG R3 ACCATGCGTCAACGTACTG 
F4 ACGCATGGTACTCTAATCAG R4 CGGCCGTTCTGATTAGAGT 
F5 AACGGCCGTAGCATCCC R5 ACGTTTCCACGGGATGCTA 
F6 GTGGAAACGTATCCCGTCC R6 CACTTCGCTGGACGGGAT 
F7 AGCGAAGTGAAACAGTTCCA R7 CACCGGTCTGGAACTGTTT 
F8 GACCGGTGAGGCGTTCA R8 ACAGTTGAAGTTGAACGCCT 
F9 ACTTCAACTGTTTCGCAACTGTTCAGCGTTTC   
 
Using the established synthesis protocol with our new deblocking conditions, we 
proceeded to synthesize the oligonucleotides needed to assemble a gene fragment from 
Bacillus cereus.  Each oligonucleotide product was verified though gel electrophoresis.  
The gel image (Figure 4-5) shows that the chip products had the same motility as 
commercially ordered standards from IDT.  The lanes with chip products were partially 
smeared because no desalting step was taken; however, the major products all 
corresponded with full-length oligonucleotides. 
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Figure 4-5:  Polyacrylamide gel electrophoresis comparing oligonucleotides synthesized from the microfluidic platform 
(Ch) to oligonucleotides purchased from IDT.  The chip products have the same motility as the commercially prepared 
standards.  However, the chip products are also partially smeared because of excess salt as no desalting step was 
performed after cleavage from the beads. 
Ligation Assembly of DNA Constructs 
To confirm the identity of synthesized sequences and to determine whether the eluted 
oligonucleotides were functional without further amplification or purification, a gene 
fragment from Bacillus cereus was assembled from a mixture of oligonucleotide 17—24- 
mers that were obtained using the microfluidic synthesis method described earlier.  The 
general strategy of gene assembly used involves ligation of oligonucleotides into a 
complete construct followed by PCR amplification of the full-length product (Figure 4-6).  
The oligonucleotides were each collected in a 10 µL volume; the material produced from 
one synthesis is sufficient for 50--100 ligation reactions. 
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Figure 4-6:  Schematic of gene assembly by ligation.  The starting oligos are placed in a single mixture and allowed to 
anneal and ligate into complete constructs.  Primers are than added to amplify the full-length product by PCR. 
 
A special set of ligation reactions with Cy3-labeled F1 strands was performed to examine 
the ligation reaction in detail by gel electrophoresis without the need of amplification 
(Figure 4-7).  Reaction pots with increasing numbers of strands that form products of 
increasing length were prepared.  We expected species of various starting and ending 
strands to be ligated in each reaction.  However, only species that included the Cy3-
labeled F1 strand could be visualized after electrophoresis.   
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Figure 4-7:  Polyacrylamide gel electrophoresis for a series of ligations reactions with a Cy3-labeled F1 strand in 
combination with different numbers of starting oligonucleotides.  No products longer than the expected length are 
present in each reaction mixture.  For example, in the mixture containing F1 through F5, only F1, F1-F2, F1-F3, F1-F4 
and F1-F5 are observed.  No products longer than F1-F7 can be visualized without further amplification.  In general, 
the amount of ligation product decreases as the number of ligation steps needed to form a particular product increases. 
 
Our results show that no products longer than the expected length are present in each 
reaction mixture.  In general, the amount of ligation product decreases as the number of 
ligation steps needed to form a particular product increases.  The majority of the Cy3-
labeled F1 strands failed to take part in any ligation reaction to form longer products.  
The longest detectable ligation product without further amplification is F1-F7.  The yield 
of this ligation reaction was not optimized.            
PCR of Ligation Product  
We performed PCR of the ligation reactions and analyzed the results on an agarose gel.   
Strong, dominant bands were evident for the desired product in lanes with the full set of 
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starting oligonucleotides.  “Primer-only” and incomplete oligonucleotide sets used as 
controls yielded no product-length bands confirming that the presence of desired-length 
species was not a consequence from amplifying a contaminating species.  We observed a 
weak band in the main reaction lanes that indicated there were lower molecular weight 
species present suggesting there could be assembly intermediates present in the ligation 
product (Figure 4-8).        
 
Figure 4-8:  Agarose gel electrophoresis showing fell-length assembly of a gene fragment from Bacillus cereus.  In the 
presence of the full set of starting oligos, full-length products are observed following amplification.  “Primer-only” and 
incomplete oligonucleotide sets used as controls yielded no product-length bands.  Weaker bands with lower molecular 
weight indicate assembly intermediates present in the ligation product. 
DNA Sequencing of Assembled Sequence 
Sequencing of microfluidic gene synthesis products unambiguously confirmed the 
identity of the gene construct.  Even though such sequencing does not directly report on 
the quality of the starting synthesized oligonucleotides, errors present in the starting 
oligonucleotides would be a source of deletions and other errors in the assembled 
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sequences.  The fidelity of the polymerase used in the amplification step may also 
contribute to any observed errors (61). 
 
Gel purification of the resulting assembled sequence was omitted to prevent the masking 
of errors.  The clones were also not screened prior to sequencing other than to confirm 
successful insertion into the cloning vector.  Thus, gene assembly products including both 
full-length species along with other incomplete, intermediate products should be detected 
in the clones. 
 
Ten clones of DNA constructs assembled from purified oligonucleotides purchased from 
IDT were sequenced.  Eighteen clones of DNA constructs assembled from 
oligonucleotides synthesized on the microfluidic synthesis chip (Chip) were also 
sequenced.  The results of this sequencing are summarized in Table 0-5.   
 
Out of the 10 IDT clones, 8 had perfect sequence while 2 had single deletions.  Out of the 
18 Chip clones, 4 had perfect sequences, 5 had single deletions, 2 had single point 
mutations, 1 had a single deletion and insertion, and 1 had a single point mutation and a 
single insertion.  More interestingly, 3 of the Chip clones were missing a stretch of 
sequence from F3-F8.  Looking more closely at the sequences of the starting 
oligonucleotides, we found that the 5 starting bases for F3 were identical to F9.  Thus, F9 
can incorrectly ligate to F2 instead of F3.  Such a problem could be avoided with more 
careful design of the starting oligonucleotide pool. 
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For the IDT clones, a total of 2 errors were found out of 1300 bases sequenced resulting 
in an error rate of 1 per 650 bp or 0.15%.  Excluding clones with incompletely assembled 
sequences, the Chip clones had 11 errors out of 1690 bases sequenced.  That is an error 
rate of 1 per 153 bp or 0.65%.  This error rate is very similar to the error of 1 in 160 bp 
given by Tian (24). 
Table 0-5:  Summary of errors in the assembly of a gene fragment of Bacillus cereus using purified oligonucleotides 
purchased commercially (IDT clones) versus the synthesis products from the microfluidic device (Chip clones) 
Error Type IDT Assembly of Oligos  Chip Assembly of Oligos 
None 8/10 4/18 
Single Deletion 2/10 5/18 
Single Mutation  2/18 
Single Insertion and Deletion  1/18 
Single Insertion and Mutation  1/18 
Sequence Truncation (missing 
oligos) 
 5/18 
Total Bases Sequenced 1300 1690 (without truncation) 
Overall Assembly Success 
Rate 
80% 22% 
Total Number of Errors 2 11 
Per Base Error Rate  1 in 650 1 in 153 
Synthesis of Long Oligonucleotide 
To test the limits of our synthesis method, we also synthesized oligonucleotides up to 40 
bases in length.  We found that at these lengths, the resulting oligonucleotides were not of 
sufficiently high quality.  We therefore added an additional capping step that was not 
used in our original synthesis of shorter oligonucleotides.  By capping unreacted bases, 
we prevented truncated sequences from further extending.  This eliminated most of the 
N-1 and N-2 oligonucleotides observed in the uncapped synthesis.  These sequences can 
lead to deletion errors in the gene assembly reaction which are problematic.   
 
Synthesis of the homopolymer A40, G40, C40, and T40 are carried out.  Results for C40 are 
not shown because of the inefficient staining of homopolymer of cystine using SYBR 
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Gold (68).  Homopolymer of guanine G40 forms a secondary structure with itself at room 
temperature and hence its motility is greatly increased.  By running the gel at an elevated 
temperature (60 ºC), the secondary structure is eliminated and the motility returns to 
normal. However, single base resolution is not possible at such a high temperature.  A 
randomly chosen mix sequence is synthesized to esure that guanine and cytosine are 
successfully incorporated in the synthesis cycle.   
 
PAGE analysis of the reactions (Figure 4-9 and Figure 4-10) shows that the dominant 
bands in the capped synthesis are from full-length product as opposed to truncated 
products from the uncapped synthesis.  By comparing the ratio of full-length product to 
the N-1-mers, we successfully calculated our deblocking efficiency to be greater than 
98.6%, which is substantially higher than that of many other PGA systems.    
 
Figure 4-9:  Polyacrylamide gel electrophoresis showing successful synthesis of oligonucleotides 40 bases in length    
 
79 
 
 
 
Figure 4-10:  Polyacrylamide gel electrophoresis showing oligonucleotides 40 bases in length synthesized under 
different conditions.  Lane 1 is a purified standard purchased from IDT.  Lane 2 is product synthesized using the 
microfluidic chip using 5% TFA deblocking solution without any capping during the synthesis.   Lanes 3 and 4 are 
products from different reaction columns synthesized using 10% TFA deblocking solution with capping after each 
synthesis cycle.  The gel image shows that the dominant bands in the capped synthesis are from full-length products, 
whereas there is a large number of truncated products in the uncapped synthesis. 
Materials and Methods 
Device Preparation and Operation  
Microfluidic devices were stored in a desiccator overnight before use.  Glass vials filled 
with molecular sieves and steel tubes (New England Small Tube Co., Litchfield, NH) 
were dried in a 180 °C oven overnight and allowed to cool to room temperature 15 min 
prior to use.  The control lines were interfaced with computer-controlled solenoid valves 
(Pneumadyne, Plymouth, MN) through steel tubes connected to Tygon tubing.  The 
control lines were primed with Krytox oil through dead-end filling.  All reagents were 
prepared fresh prior to experiments.  Glass vials filled with reagent were connected to the 
device via microbore PTFE tubing through the septa.  5 µm, 500Å control porous silica 
beads functionalized with universal linker (SynGen) were used to construct the bead 
columns.  Both reagent delivery (10 psi for acetonitrile, 5 psi for others) and valve 
actuation (35 psi) were controlled using argon gas.  
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Polyacrylamide Gel Electrophoresis 
The synthesized oligonucleotides were re-suspended in water and normalized to a 
concentration of 50 ng/µL using a NanoDrop 1000 (Thermo Scientific).  Before gel 
loading, the oligonucleotides were mixed with TBE-Urea sample loading buffer 
(Invitrogen) and heated to 70 ºC for 3 minutes.  1.5 µL of samples were loaded onto 
polyacrylamide gel (15% Novex® TBE-Urea gel, Invitrogen).  Samples approximately 
20 nucleotides in length were run at room temperature at 175 V for 75 min.  Samples 
approximately 40 nucleotides in length were run under the same conditions but for 100 
min. The gels were stained with SYBR Gold dye and visualized using Typhoon 9410 
(Amersham Biosciences).  Final images were analyzed using ImageQuant (Amersham 
Biosciences). 
Ligation Assembly of DNA Constructs 
Each oligonucleotide strand (8 µL, 5 µM) was mixed with 1 µL of T4 polynucleotide 
kinase reaction buffer (New England Biolabs) and 1 µL of 10 mM ATP and then cooled 
to 4 ºC.  Afterwards, 0.7 µL of T4 polynucleotide kinase was added.  The mixture was 
allowed to react for 1 hr at 37 ºC and then terminated by heating the reaction mixture to 
65 ºC for 15 min.  The phosphorylated oligonucleotides were then added together and 
diluted into a 75 nM solution.  1 µL of Taq DNA ligase reaction buffer and 0.75 µL of 
Taq DNA ligase were added to 9 µL of phosphorylated oligonucleotide solution.  The 
mixture was heated to 65 ºC for 30 sec to ensure all the oligonucleotides were melted off.  
The ligation reaction was then allowed to take place at 42 ºC for 4 hrs.   
81 
 
 
PCR of Ligation Product  
Polymerase chain reaction was performed with 100 µL of reaction mixture including 10 
µL PCR buffer, 3 µL of 50 mM MgCl2, 2 µL of Primer A1 (10 µM), 2 µL of Primer B1 
(10 µM), 1 µL of dNTPs, and 1 µL of ligation mixture.  The PCR was conducted using 
the following conditions: 2 min initial denaturation at 94 ºC, followed by 20 cycles of 94 
ºC for 45 s, 55 ºC for 30 s, and 72 ºC for 1.5 min.   
DNA Sequencing 
PCR products were sequenced to check for errors.  The DNA construct was cloned using 
plasmid vector pCR®4-TOPO (Invitrogen) and transformed into OneShot® TOP10 
Chemically Competent E. coli cells.  The cells were spread on prewarmed LB plates 
containing 50--100 µg/ml ampicillin and incubated at 37 ºC.  After overnight growth, the 
plates were sent to MCLab where individual colonies were amplified and sequenced. 
Conclusion 
This novel microfluidic synthesis platform addresses many of the limitations associated 
with microarray technology such as reduced product purity due to poor deprotection, 
insufficient synthesis scale, and adverse interactions in large oligonucleotide pools, while 
keeping many of its advantages (such as reduced cost).  Our chip is programmable for 
synthesis of any desired sequence, easy to operate, and consumes very minute quantities 
of reagent and solvent on a per sequence basis.    
 
The new deblocking scheme used in our platform rivals optical and electro-chemical 
deprotection strategies which are currently in development in both cost and efficiency.  
Unlike other systems where complex mixtures of custom chemicals are needed (70), our 
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deblocking solution only uses dilute trifluoroacetic acid which is commercially available.  
The efficiency of our deblocking step is estimated at > 98.6% which is higher than the 
PGA system used by Affymetrix (97%) as well as other photocleavable protecting groups 
(94 %) (23).   
 
The physical separation of individual reaction chambers eliminates the potential problem 
of cross contamination.  Having individually addressable valves gating each reaction 
chamber also allows for easy recovery of specific sequences synthesized for direct use in 
the subsequent gene assembly.  This is especially useful for multiplex reactions where 
sequences with adverse interactions with each other can be eluted into different mixtures.  
Such precise fluid handling is not available in microarray technologies and will help 
allow the integration of this chip into other processes in the future.    
 
The oligonucleotides synthesized from our device were directly used for ligation to give 
DNA constructs about two hundred base pairs long.  Employing such direct synthesis 
without concentration or an initial amplification step not only reduces the time and cost 
of the overall synthesis protocol, but also eliminates the possibility that additional errors 
will be generated during the amplification procedure.  While the error rate of 1 in 153 bp 
from chip product is higher than that observed for a product assembled from purified 
oligonucleotides ordered from IDT, it is consistent with the 1 in 160 bp error rate given 
by Tian for assembly of DNA constructs using unpurified oligonucleotides.  The 17—24-
mer synthesis also lacked capping. Given the improvement in purity for longer syntheses 
(Figure 4-9), performing capping during the synthesis of the oligonucleotides used for 
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ligation should similarly improve error rate.  Optimized ligation conditions, including 
varied temperature, may also be able to minimize the incorporation of errors into the full-
length product.   
 
These results demonstrate significant progress towards high-throughput gene synthesis 
and could help meet the growing demands of the emergent field of synthetic biology.  
Substantial improvements are still needed but many can still be achieved through further 
optimization of reaction conditions.  Systems integration of other processes that have 
already been demonstrated in stand-alone units, such as purification, cloning, and protein 
expression (71), will greatly increase the range of suitable applications for this 
technology. 
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Chapter 5  
FUTURE STRATEGIES FOR MASSIVE PARALLEL OLIGONUCLEOTIDE 
SYNTHESIS   
Introduction 
Microfluidic devices have evolved rapidly from early single-channel structures to 
complex devices that perform hundreds of assays in parallel and that integrate multiple 
sample preparation and analysis operations.  The development of pneumatic valves that 
allow for dense fabrication and parallel actuation of hundreds or even thousands of valves 
has been instrumental in the creation of more complex devices.  However, independent 
control of large numbers of valves is still very difficult because in most cases each 
independent valve requires a dedicated off-chip solenoid valve.  The size and cost of 
these off-chip controllers impose a practical limit on the number of independent 
pneumatic valves in a device.   
 
In the synthesis of oligonucleotides, each reactor column must be independently 
addressable for the operation to be parallelized.  Using the current design architecture, 
one off-chip solenoid valve would be needed for each desired sequence to be synthesized.  
However, for the assembly of a gene of moderate size, hundreds of distinct 
oligonucleotides would be needed.  Given the cost of 20 USD for a typical solenoid valve 
used for microfluidic devices, a system capable of synthesizing so many oligonucleotides 
would cost upwards of 2,000 USD without consideration of the additional cost of the 
digital I/O cards needed to interface the valves to a computer. 
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If valve control circuitry could be integrated onto the microfluidic device, then the 
number of off-chip controllers needed for complex control tasks could potentially be 
reduced to a much smaller number.  In principle, a large number of independent valves 
can be actuated by a single pressure controller using time-division multiplexing.  This can 
be implemented provided that a valve can remain actuated for a period of time sufficient 
for the external control to cycle back to it. 
 
Another strategy is to embed the sequence information of oligonucleotides to be 
synthesized in the layout of the control lines themselves.  A device utilizing this strategy 
can only be used to synthesize a specific set of oligonucleotides.  However, while the 
high start-up and fabrication costs of silica microfluidic devices make it infeasible to 
make single-use devices, the fast turnaround time and economical fabrication costs of 
MSL devices make such a strategy reasonable.    
 
Novel Control Scheme for Reactor Addressability 
Time-Divison Multiplexing through “Control of Control” 
In electronics, a multiplexer (mux) selects one of the many analog or digital input signals 
and forwards the selected input into a single output line.  A microfluidic multiplexer 
serves the same function and is a powerful tool that addresses a large number of lines 
with a small number of connections to outside controls.  The most common way in which 
a multiplexer is implemented is through an array of complementary valve pairs organized 
in a binary architecture to select 1 of 2N flow lines using 2N control lines.  Each selection 
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bit corresponds to two control lines, and the lines for each bit will always be in 
complementary states, for example ܤ݅ݐ 1 and ܤ݅ݐ 1. 
 
Figure 5-1:  Schematic of a binary multiplexer 
 
While a multiplexer with even higher efficiency than the binary multiplexer has been 
demonstrated that uses a strategy that allows N!/(N/2)!2 lines to be addressed using N 
control lines (72), it is very difficult to decode the exact line being addressed from the 
select bits.  In the case of the binary multiplexer, the binary value of the selected bits 
specifies which line is being addressed.  For example, a set of selection bit valves can be 
represented in binary as 1110, which corresponds to a decimal value of 14, and line 14 is 
being selected (Figure 5-1).  Conversely, a demultiplexer (demux) takes a single input 
signal and selects which one of multiple outputs the input is passed to.  In microfluidics, 
the implementation of a demux is exactly the same as a mux but the direction of flow is 
reversed.   
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Normally, the use of muxes and demuxes is used primarily in the fluidic layer.  However, 
Todd Thorsen proposed and demonstrated the concept of using a demultiplexer to 
selectively actuate control lines which in turn actuate valves, termed “control of control”.  
“Control of control” can more easily be understood if one were to imagine an 
intermediate component that is a microfluidic analog of an electronic dynamic random 
access memory (DRAM).  An electronic DRAM is an array of memory cells that stores 
information as voltage potentials, with the defining characteristics of being randomly 
accessible and dynamic.  The random access aspect of a DRAM is expressed as the 
ability of each cell to be uniquely addressed and written to with the same ease as other 
cells.  And because the stored potentials decay over time, requiring that they be actively 
refreshed at regular intervals, the memory can be described as dynamic.  A microfluidic 
DRAM has both of these characteristic.   
 
For a microfluidic DRAM, each cell is a control line, and the demux in the base level is 
used to address specific cells.  By connecting a high pressure source to a cell, one sets the 
state of the cell to be high, and by connecting a low pressure source to a cell one sets the 
state of the cell to be low.  Since each cell inside the DRAM corresponds to a control line 
on the top level, if the cell is in a high pressure state, then all the valves associated with 
that control line are closed.   If the cell is in a low pressure state, then all the valves 
associated with that control line remain open.  One actuates the valves on the top level by 
changing the states of the cells inside the DRAM in the intermediate level.  Because only 
one demux output is being controlled at once, the pressure in the cells not currently being 
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controlled will decay as the control fluid leaks (through opening in valve or evaporation), 
and so the values of all of the cells must periodically be refreshed.   
 
Figure 5-2:  A 32 compartment DRAM.  The simplest DRAM can be implemented using only a single demux.  The two 
inputs to the right correspond to a high pressure source and a low pressure source.  The top five control lines (yellow) 
correspond to the 5 select bits needed to address the 32 compartment, the bottom five control lines are their 
complements.  The 32 channels (red) in the row array are the compartments and the large pads at the end of each 
compartment are the valves.   
The Use of DRAM for Actuation of Valves 
To demonstrate the functionality of the DRAM for actuation of valves, a fluidic layer 
with 32 channels is added on top of the DRAM to make actual valves.  The threshold 
pressure for the valve is highly dependent on the geometry of the intersection, thus valves 
are only formed at the end of each row.  This array of 32 valves is used to characterize 
the performance of valves with dimension and operating conditions similar to those found 
on the microfluidic DNA synthesizer.  
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Figure 5-3:  A 32 valve array controlled using DRAM 
Regarding the dynamic aspect of the DRAM, the two most important attributes are the 
speed at which cells can be written and the length of time cells can hold their states 
before they lose their values.  The former determines how fast the valves can be actuated, 
and the latter determines how often the DRAM has to be refreshed.  The maximum 
number of valves that can be independently controlled will be the ratio of these two 
attributes.  The speed at which the state of each chamber can change (write time) is 
highly dependent on the actuating time of the selection control lines.  If a write event 
occurs before the proper chamber is selected, the wrong chamber might be assigned or 
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other chambers can be affected through cross talk.  Using oil-filled selection lines, a 
minimum write time of approximately 1 second per chamber is achieved.  This translates 
to about 0.5 min to completely set the state of the entire DRAM.  For the specific 
application of DNA synthesis, each column valve has to actuate twice per four coupling 
steps.  That averages to N/2 seconds of wait time before each coupling step, where N is 
the number of reactor columns.  The wait time can be dramatically reduced by switching 
to a fluid with a lower viscosity or even an inert gas.  While the use of oil is not optimal 
from the point of speed, the ability of the DRAM to maintain its states using oil is superb, 
as valves remained closed at the termination of a timing test which lasted over 2 hours.  
Because of the low vapor pressure of oil, it will not vaporize and escape through the 
porous PDMS matrix.  With either water or inert gases, the loss of the pressure within the 
compartment would be much quicker.  An ideal liquid to be used in the implementation 
of “control of control” should have low viscosity, low vapor pressure, and be compatible 
with PDMS.    
Design Considerations 
“Control of control” can be implemented in either a three-layer device or a two-layer 
device.  Depending on the applications, one option might be more suitable than the other.   
For “control of control” to be implemented in a two-layer device, the thin layer that is 
normally used exclusively as the fluidic layer in the push down configuration needs to 
double as a control layer for the demux  as well.  Thus, one would use a push up 
configuration to implement the control of the demux in the thin layer.  A hybrid or mold 
is used in the thick layer to create channels that have both square and round profiles.  The 
round section would be the fluidic lines of the demux; the square section would become 
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the control channel to the fluidic lines in the thin layer.  The different profiles make 
identification of the role of each channel easier; however, a round mold can be used as 
well. 
 
While having both the thick and thin layers double as control and fluidic layers allows 
devices to be made using the normal protocol, routing could be problematic in devices 
with high valve density.  This configuration should only be used if the fluidic channels 
have to come into direct contact with a modified glass surface, such as in a DNA array.  
Oxygen plasma bonding to the glass substrate is not an option because it would destroy 
the modified glass surface.  Thus, the select control lines cannot be operated at a pressure 
greater than 20 psi.  Assuming that actuation pressure is 5 psi for a push-up valve and 10 
psi for a push-down valve,  the highest pressure that can be used in the top level fluidic 
channel would only be 5 psi. 
 
In a three-layer device, the control channels of the demux would be present in their own 
layer, simplifying routing.  Because a push-up configuration is used for the top level 
fluidic layer, one is allowed to have greater channel height, which would be 
advantageous for applications requiring the use of large beads, or the manipulation of 
eukaryotic cells (13).  Because oxygen plasma bonding could be used to bond to the glass 
substrate, the select control lines could operate at pressures as high as 35--40 psi.  
Assuming that actuation pressure for push-up valves is 5 psi, reagent pressure as high as 
25 psi could be used.  This is especially useful in DNA synthesis where 15 psi pressure is 
used during the washing step for quick removal of residual chemicals.    
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Figure 5-4:  Cross-sectional view of two-layered and three-layered implementation of “control of control” device  
 
Another consideration for the design of DRAM is the volume of the cell compartment.  
The size of the compartment is proportional to the capacitance of the DRAM cell.  While 
smaller cell compartments can lead to a modest reduction in the write time, a critical 
volume is needed such that the states in each compartment cell can withstand a certain 
amount of noise and leakage.  Using a conservative addressing scheme to cycle through 
all the cells in DRAM, the amount of oil trapped in a given compartment could increase 
by N times the valve volume, where N is the number of selection bits.  If the 
compartment of the cell is small, the increase in amount of oil inside the compartment 
can cause a great enough pressure change so the state goes from low pressure to high 
pressure.        
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There are also instances where the number of control lines needed to implement a demux 
for use in a DRAM can be reduced further.  In cases where the state of each cell is not 
important while it is being written, the number of control lines can be further reduced to 
N.  Instead of having two control lines for each select bit, the complementary control line 
can be omitted as long as a special addressing scheme to write the cells is followed.  For 
example, in a 3 bit system, one can write the state of line 0 into all lines with all control 
lines open (binary 000).  In select state of (binary 001), and one can write the state of line 
1 into lines 1--7.  In select state of (binary 010), one can write the state of line 2 into lines 
2--7.  In select state of (binary 011), one can write the state of line 3 into lines 3--7.  In 
select state of (binary 100), one can write the state of line 4 into lines 4--7.  By the time 
select state of (111) is chosen, one sets the state of line 7 and the entire DRAM is now at 
the proper state.   
Custom Sequence Specific Oligonucleotide Synthesizer 
Instead of having a single valve that can be independently actuated to control the flow of 
reagent into a reaction column, one could  have multiple valves that each control the flow 
of reagent into a reaction column for a particular step.   
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Figure 5-5:  Schematic of control lines for sequence specific oligonucleotide synthesizer 
  
The sequence information is directly encoded into the layout of the control lines, so there 
is no need for a complex program that changes depending on the oligonucleotides to be 
synthesized.  The complex operation of determining which valves to actuate would be 
replaced by a straightforward sequential actuation of control lines.   
 
Each control line controls fluid flows into all reactor columns for a single coupling step.  
For example, in Figure 5-5, the control line A1 controls the coupling of the adenosine at 
the first position of oligonucleotide to be synthesized. Similarly, C3 controls the coupling 
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of cytosine at the third synthesis position.  Using the above control lines, the 4 sequences 
that will be synthesized from top to bottom are TTC, CTA, GCG, and AAC.   
 
An advantage of using this control scheme is that the control lines can be extended to 
manage hundreds or even thousands of columns in parallel.  The number of control lines 
needed is determined solely by the length of the desired sequence and not by the number 
of columns.   Because each control line only controls a single coupling step, four lines are 
needed for each synthesis cycle.  For 32 base oligonucleotides, 128 control lines would 
be needed.  If one were to combine a demux with this control scheme, the total number of 
outside control valve for addressing the reactor columns be would reduced to 14. 
Column Array Construction  
The construction of a reactor arrays with uniform flow rate and capacity becomes 
increasingly challenging as the number of reactors increases.  While serial packing of 
reactors can often ensure the quality of the bead column being formed, it leads to an 
increase in preparation time as well as the need for additional outside controls that are 
already scarce, especially when large numbers of columns are needed.   
 
In order to save time and reduce the number of preparation procedures, a design that 
accommodates parallel loading is preferred.  In an initial design beads fill a channel that 
has a large compartment (shown in red in Figure 5-6) dedicated to each column.  Once all 
the compartments are filled, valves portion off each reactor, and the beads are flushed 
against the sieve valve by a binary tree to the left.  The number of beads flushed into the 
column valve depends on the size of the compartments in the bead loading channel.  
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Multiple iterations of filling the compartments with beads and flushing the beads into the 
column will eventually fill the reactor columns with beads.  
 
Figure 5-6:  The red line marks the bead compartment within the vertical bead loading channel.  (A) Valves are 
portioned of the compartment and the beads are pushed against the column valve to the right.  (B) Two iterations of 
bead filling and flushing are completed.  The leftover beads within the vertical bead loading channel run are flushed out.   
 
In a later design, the compartments within the bead loading channel are removed to 
further streamline the process.  Instead, the beads directly fill the reactor columns during 
the bead loading process.  The size of the column reactor now controls the number of 
beads being loaded, not the size of the compartment in the previous design.  The detailed 
process is shown in Figure 5-7.    
 
97 
 
 
 
Figure 5-7:  Schematic illustration for construction of the bead column in the microfluidic oligonucleotide synthesizer.  
Valves with cross bar indicate they are closed during that operation.  Otherwise they remain open.  (A)  The 
addressable inlet valves are all closed and the bead suspension is loaded from the top.  The top column fills first 
because it is closest to the bead inlet.  However, as the beads pack, the resistance to the column increases and more 
beads are carried into the later columns.  (B) Once all the columns are fully packed, the set of sieve valves closest to the 
inlet is closed to prevent beads from escaping.  (C) Acentonitrile is flushed from the bottom to remove any excess 
beads that are not inside the column.  (D) After the excess beads are removed, the valves between columns are closed 
to separate the columns from each other.  The compression valves are also actuated to prevent rearrangement of beads 
when pressure drops occur between synthesis steps, thus minimizing bead loss. 
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During bead loading, it is important that the pressure within the column array is 
maintained or increased with each successive step until the columns have been packed.  
Otherwise, there is an increased probability of beads becoming trapped within the vertical 
channel, which may prevent the valves from fully closing and could lead to crosstalk 
between adjacent reactor columns.  At higher pressures, the cross-sectional areas of the 
channels are larger due to the elastic nature of PDMS.  If the pressure were to suddenly 
drop, the channel height would decrease and beads that could previously just barely pass 
through the section will now become clamped down and unable to move.   
 
 
 
Figure 5-8:  Schematics for the various column arrays tested.  (A) Overview of the column array.  (B) Close-up of 
various configurations tested.  (B1) Long column length with small column valve.  (B2) Short column length with 
small column valve.  (B3) Long column length with big column valve.  (B4) Short column length with big column 
valve 
 
 
To optimize the performance of the column array, several parameters were tested, 
including the column valve sizes, the length of the reactor columns, and the profile of the 
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binary tree.  The different configurations tested are shown in Figure 5-8.  Actual flow 
rates of each column in each of the configurations were measured and normalized.  
Standard deviation is then computed to reflect the uniformity of the flow rate between 
columns.  The values for the standard deviation are summarized in Table 0-1 
 
Table 0-1: Measurement of flow rate uniformity between columns under various configurations 
 Column Array Configuration 
 long column 
small valve 
long column 
large valve 
short column 
small valve 
short column 
large valve 
run 1 0.097 0.122 0.129 0.305 
run 2 0.093 0.126 0.154 0.247 
run 3 0.070 0.121 0.111 0.233 
 
The results suggest that the uniformity increases with increasing column length.  This 
finding is not surprising, as deviations due to irregular bead packing are more likely to be 
averaged out in longer columns.  What is surprising is that the size of the column valve 
has a large impact as well.  In designing the column valves, it is desirable that they be just 
large enough to trap the beads.  While, having larger column valves can ameliorate the 
escape of beads between synthesis steps, it has an adverse affect on the uniformity of 
flow rate.  This has to do with the size of the beads compared to the size of the opening at 
the edge of the columns when the column valve is deflected.  Under the current valve 
geometry, the openings at the edges of the channel are larger than the beads.  For the 
column to be packed, the opening is clogged by a stochastic staggering of beads that 
prevents them from passing through the opening one by one.  Having a larger column 
valve can lead to more variability as seen in Figure 5-9.   
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Figure 5-9:  Illustration of how beads are packed against column valves with different valve size.  As this figure shows, 
having a larger column valve permits more variability in the staggering arrangement of beads at the edges of the 
channel.    
 
A problem that surfaces after many cycles of synthesis is the gradual loss of beads 
between steps.  In between synthesis steps, pressure changes in the reactor column cause 
rearrangement of the packed spherical beads, and those at the edges of the column valve 
have a chance to escape through the opening.  As discussed, a larger column valve cannot 
be used because it could contribute to uneven flow between the columns.   Additional 
sieve valves, denoted as compression valves, were added to the middle of the columns to 
press down against the beads to prevent rearrangement of closely packed spherical beads.  
Using this design over 95% of resin was retained after 40 cycles (20 hr) of synthesis. 
 
Squared profile channels are used in the construction of binary tree because flow velocity 
is much more constant across the width of a square channel compared to the parabolic 
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velocity profile associated with rounded channel.  The final design is then implemented 
into the parallel microfluidic DNA synthesizer described in Chapter 4.    
In Situ Construction of Reactive Sites 
While a successful column array was designed and fabricated for 16 columns, it is 
difficult to envision parallel loading of similar column array scaling up to over 100 
columns.  The time needed to construct columns prior to use for thousands or hundreds of 
thousands of distinct oligonucleotides may be significant.  Also if the columns were to 
continue to shrink in size so more could fit on a chip of a similar size, the flow rates in 
each column may become more uneven.  One solution to these problems is to modify the 
PDMS surface so that it is much more glass-like, thus allowing further coupling of linker 
directly onto the column surfaces.  The synthesis sites will now be directly on the device, 
and there is no longer any need to pack columns of solid phase support.   
 
Oxidation of the PDMS channel walls is one of the most popular routes for covalently 
modifying the surface (73,74).  Surface oxidation using an oxygen plasma is followed by 
simple silanol condensation chemistry for the attachment of 3-aminopropyl on the 
channel surface (75).  However, the free silanol groups on the surfaces of PDMS are 
transient, and a progressive restoration of hydrophobicity occurs as free PDMS chains 
move to the surface and the silanol groups become buried (76).  Thus any modification to 
the surface must be performed quickly and would face issues with longer term stability.  
From the standpoint of device fabrication, surface-modified PDMS poses additional 
challenges with device assembly and channel sealing because bonding can only occur 
after the appropriate chemistry has taken place.  As a result, the current method of 
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bonding between partially cured layers is no longer applicable because it has to be done 
within 2 hr of curing.   
Sol-Gel Modified Poly(dimethylsiloxane) 
A potential alternative method for modifying the surface (and bulk) properties of PDMS 
is to use sol-gel process to form nanometer-sized particles throughout a polymerized 
PDMS matrix (77--79).  To form the particles, an alkoxysilane precursor such as 
tetraethyl orthosilicate (TEOS), which is soluble in the polymerized PDMS, is first 
hydrolyzed.  Particles are then formed through the condensation of the hydrolyzed 
silanes.  The condensation is generally catalyzed using either an acid or base.  Spherical 
particles are expected in the case of base-catalyzed reaction while linear chain growth is 
anticipated via acid catalysis.  This process results in the generation of permanent free 
silanol groups at the surface as well as within the matrix of the PDMS, thereby allowing 
the wide range of surface modifications developed for glass to be used on these modified 
PDMS devices.    
 
Si(OC2H5)4 + 4 H2O → Si(OH)4 + 4 C2H5OH (hydrolysis) 
Si(OH)4 + Si(OH)4 → (HO)3Si-O-Si(OH)3 + H2O  (condensation) 
 
The diameter of the silica particles generally increases with increasing concentration of 
base (80).  While the modified bulk PDMS displays a higher Young’s modulus, the 
increase is not high enough to affect the closing of valves in push-up configuration.  
However, it could become a problem for push-down valves.    
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Evaluation of Amino-Grafted Reactor Chamber 
The silanol-covered PDMS surfaces were treated with 3-Aminopropyltriethoxysilane 
(APTES).   A constant flow of neat APTES was maintained for 1 hr at room temperature 
to complete the silanization reaction.  Dry acetonitrile was used to remove unreacted 
silane.  To quantify the amount of NH2 on the surface of reactor, FAM fluorescein was 
coupled onto the surface though a peptide bond.  For comparison, amine slides were 
purchased from ArrayIT® and coupled with FAM under the same conditions. 
 
Figure 5-10:  Quantification of Amino group present in sol-gel modified device compared to amine slide purchased 
from ArrayIt.  (A) Sol-gel modified device coupled with FAM fluorescein.  (B) Amine slide coupled with FAm 
fluorescein 
 
The images were analyzed using ImageQuant (Amersham Biosciences).  An amino group 
density of approximately 3.3 pmol/cm2 was assigned to the signal strength obtained from 
the amine slides, based on their specifications.  The density of amino group on the sol-gel 
device is calculated to be approximately 3.8 pmol/cm2 by comparing the average signal 
intensity inside the reactors of the two images.  The image appears much darker for the 
sol-gel device because amino groups are present on the floor and the ceiling of the reactor, 
compared to the amine glass slide, which only has amino groups on the floor.   
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While the density of the amino group in the sol-gel device compares favorably with that 
of commercialized amine slides, using this setup, one can only hope to double the amount 
of oligonucleotide synthesized using equivalent microarray technology.  Yield can be 
further improved by increasing the surface area inside the reactor columns.  One strategy 
is to construct an array of cylindrical posts to increase the total surface area inside the 
reactor.  However, for each post the area of the wall created is 2πrh and the area lost from 
floor and ceiling is 4πr2.  Thus the aspect ratio (height-to-width ratio) of the post must be 
greater than 1 for the total area to increase.  In the various attempts to make such 
structures, the PDMS posts very often got stuck in the mold and would be torn off in the 
process of device fabrication.  To address this problem, pyramids or cones could be used 
instead of posts, as their sloped surfaces are easier to peel off.   
Materials and Methods 
Device Preparation and Operation for “Control of Control” 
The demux control lines were interfaced with computer-controlled solenoid valves 
(Pneumadyne, Plymouth, MN) through steel tubes connected to Tygon tubing, and were 
primed with Krytox oil through dead-end filling.  The high pressure source for the 
DRAM was connected to the microfluidic device through Tygon tubing.  The low 
pressure inlet of device was left open to the atmosphere.  Before use the DRAM was also 
primed with Krytox oil through dead-end filling.  The demux control lines actuation (35 
psi) and the high pressure source for DRAM (20 psi) were controlled using nitrogen gas. 
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Sol-Gel Modification  
A three-layer device is initially made without holes punched, and cured for 24 hours 
instead of the normal 8 hours before use.  Next, it is immersed into pure TEOS for 2.5 
min, allowing it to penetrate and swell the PDMS matrix.  The device is taken out and 
dried completely.  Then the device is immersed in a 4% methylamine solution in water 
for 5 hours and subsequently baked at 95 ºC for 1 hour.  Finally, the inlet, outlet, and 
control holes are punched and the finished device plasma bonded to a glass slide (70 W, 
300 mTorr, 15 sec).      
Conclusion 
 
We have discussed some issues with massive parallelization of DNA synthesis using our 
current microfluidics platform.  The two most pressing problems are the need for 
additional control circuitry within the microfluidic device to eliminate the need for off-
chip controllers that could be costly and difficult to interface, and the ability to construct 
thousands of reaction chambers with high uniformity to carry out the synthesis of a 
massive number of oligonucleotides.  Possible solutions are proposed and tested.  Using a 
custom synthesis device in conjunction with “control of control” the number of control 
lines needed to control an arbitrary number of reactors for synthesis of oligonucleotides 
40 bases in length can be reduced to 14, which is two less than the number currently 
being used to control the 16 column device. 
 
The issues associated with the construction of the bead columns are more complex.  One 
can choose to deravitize the surface of PDMS with amino groups so that universal linkers 
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used in CPG can be directly coupled to the column surfaces.  However, the scale at which 
the oligonucleotide can be synthesized is now similar to other microarray technology.  
The yield can be improved by making rough features that increase the overall surface 
area, however, it will be difficult to approach the scale of CPG.   
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Appendix A 
Solution-Phase Surface Modification of Poly(Dimethylsiloxane) Microfluidic Devices 
Introduction  
In the last decade, there has been a shift away from glass and silicon microfluidic devices 
to those made of polymer substrate because of the time-consuming and expensive 
fabrication process associated with the former two (74).  Some of the polymer materials 
that have been used for device fabrication are poly(methylmethacrylate) (PMMA),  
polyvinylchloride (PVC), polycarbonate (PC), polystyrene (PS), polyurethane and 
poly(dimethylsiloxane) (PDMS) (81--83).   Of all the polymers used, PDMS has been the 
most popular for a number of reasons.  By using soft lithography, a technique introduced 
by Whitesides’ group, multiple PDMS devices can be made from a single master by 
replica molding (84).  The elasticity of PDMS also allows active valves to be made in situ 
for further manipulation of fluids.  PDMS is biologically inert and non-toxic, making it 
suitable for various biological applications.  The porous matrix is permeable to gases, 
allowing various gases to be supplied into closed cell culture systems (85).  Lastly, it has 
excellent optical properties, allowing transmission of light down to wavelengths of 280 
nm.    
 
In spite of the many advantages of PDMS, its application in microfluidics has not been 
without problems.  The surface modification of PDMS is difficult because the material is 
inert.  Furthermore, PDMS is extremely hydrophobic.   As a result, PDMS readily 
absorbs nonpolar organic solvents and small hydrophobic analytes, causing fouling of the 
material (86).  Several approaches have been developed to confer certain surface 
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properties such as hydrophilicity to PDMS to make it more attractive in certain 
applications.  Grafting of common tethering groups such as amine and thiol (75,87) to the 
PDMS surface also allows subsequent attachments of molecules further altering its 
properties.  The most common approach is to expose the PDMS to an energy source such 
as oxygen plasma, ultra-violet light, or corona discharges (76,88,89).  While the exact 
mechanism is not clearly understood, exposure to corona or oxygen plasma causes 
formation of a SiOxsilica-like layer with higher oxygen content than bulk PDMS through 
oxidation.  At the end of this process, the silane groups on the PDMS are replaced by 
silanol groups.  The effect is, however, transient, as progressive restoration of 
hydrophobicity is often observed minutes after the oxidative treatment.  Further 
silanization of the freshly created silanol-covered surfaces introduces functional groups 
that enable desired surface properties and slow hydrophobicity recovery to weeks.  From 
the standpoint of device fabrication, surface-modified PDMS poses additional challenges 
for device assembly and channel sealing because bonding can only occur after the 
appropriate chemistry has taken place.  As a result, the current method of bonding 
between partially cured layers can no longer be used because it must be done within 2 hr 
of curing. 
 
We propose an improved approach that consists of a solution-phase oxidation reaction in 
acidic H2O2 solution and a sequential silanization reaction using neat silane reagents for 
surface modification of intact microfluidic channels that are embedded in multilayered 
PDMS devices.  In contrast to the conventional approaches, this method has the 
advantage of simple and convenient handling suitable for routine practices in both 
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chemistry and biology laboratories, with no need for specialized instruments such as 
oxygen plasma or UV light sources.  Because the reaction takes place after the device has 
already been assembled, there are no issues with bonding between layers during device 
fabrication.  And by switching to neat silane instead of diluted silane or vapor deposition, 
we also found that the resulting surface modification is more stable and remains intact for 
months after the derivatization. 
 
Using this method, different functional groups were introduced onto PDMS surfaces for 
different purposes.  PEG was used to limit nonspecific protein absorption onto the PDMS 
surface while amine groups were grafted for further attachment of bio-molecules and 
other chemical groups.  X-ray electron spectroscopy (XPS) and contact angle 
measurements were used to characterize the surface of the PEG-grafted PDMS substrate 
and to track temporal changes.  A variety of fluorescent protein solutions were flowed 
through the PEG-grafted PDMS channels to test whether the PEG group reduces 
nonspecific binding.  Time-lapse images were taken showing that the protein repelling 
characteristic enhanced progressively over the initial 24 hour period and persisted for 
over two months. 
 
Amino-grafted PDMS channels were created using similar protocols and further modified 
with tripeptide (RGD), and a soluble, recombinant form of prostate stem cell antigen, 
PSCA (90).  Using these biomolecule-covered PDMS channels, cell immobilization and 
incubation and immunoassay were demonstrated on a miniature scale, with the additional 
benefits of chemical/sample economy and operational efficiency.  
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Solution-Phase Surface Modification  
Modification of microfluidic channels starts from the solution-phase oxidation reaction of 
PDMS surface, which was carried out by continuously passing a mixture of 
H2O/H2O2/HCl (5:1:1) through the channel for 5 min.   The channels were then purged 
with DI water and dried with argon, leaving the hydrophilic silanol-covered PDMS 
surfaces.   After that 2 methoxy(polyethylenxy)propyl)trimethoxy-silane was injected 
into the silanol-covered  channel to perform the silanization reaction at room temperature 
for 30 min.  The unreacted silane was flushed from the channels by water to give the 
PEG-grafted channel surfaces, which were dried by argon flow and preserved in a 
ambient condition for various periods of time prior to the protein repelling studies. 
 
Similar to the preparation of the PEG-grafted microfluidic channels, the silanol-covered 
channels were reacted with (3-aminopropyl)trimethoxy silane to generate the amino-
grafted PDMS surface.  The surface-grafted amino groups were converted to 
isothiocyanate groups by introducing a 0.5% thiophsgen solution in acetonitrile into the 
amino-grafted channels.  Again, after purging with DI water and dry Argon, the 
isothiocyanate-grafted PDMS channels were subjected to attachment reactions with 
amino-terminated tripeptides or prostate stem cell antigens.  These biomolecule-grafted 
channels were subsequently washed with phosphate-buffered saline (PBS, pH 7.4) or 
Tris-buffer solutions (pH 7.4) and preserved at 4 C for at least 24 hr prior to their 
respective studies. 
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Surface Characterization using XPS and Contact Angle Measurements  
Bulk PDMS substrates were treated using the same surface modification protocol to give 
silanol-covered substrate and PEG-grafted substrate for subsequent surface 
characterizations.  XPS was utilized to validate the functional group transformation on 
the PDMS substrates.  The XPS spectra of the untreated PDMS substrate exhibits a ratio 
of 1.3:1 between O 1s and C 1s photoemissions, while the spectra of the PEG-grafted 
substrate exhibits a ratio of 1.6:1.  In the high-resolution XPS spectra (shown in inset of 
Figure A-1), an O-linked C 1s peak centered at 281.3 eV, characteristic of PEG chains, 
emerges for the PEG-grafted PDMS but not for the unmodified PDMS.    
 
Figure A-1:  XPS spectra of unmodified PDMS substrate and PEG-grafted substrate  
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Temporal contact angle measurements were used to monitor the dynamic surface 
characteristics of the silanol-covered substrates as well as of the PEG-grafted substrates.  
For comparison, the untreated PDMS substrate served as a control.  Similar to the 
oxygen-plasma-treated PDMS surfaces, the silanol-covered substrates obtained by the 
H2O2/HCl treatment shows gradual recovery of their hydrophobicity characteristics 
within 24 hours when the substrates were stored in an ambient environment. 
 
The PEG-grafted substrates exhibited a relative lower hydrophilicity after initial surface 
modification.  However, the recovery of hydrophobicity in the PEG-grafted substrates 
was slower.  At their steady states, the PEG-grafted substrates have lower contact angles 
than substrates that only underwent oxidative treatment.  These results suggest that a 
robust cross-linked PEG silane layer using neat silane reagent exhibits long-lasting 
hydrophilicity.  Control experiments in which diluted silane solution were employed for 
the PEG modification showed poor fidelity in surface stability.   
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Figure A-2:  Measurement of advancing (blank square) and receding (solid square) contact angles of water on PEG-
grafted substrates and silanol-covered substrate compared to unmodified PDMS.   
Protein Repelling Characteristics of PEG-Grafted Substrate 
To further investigate the surface properties of these PEG-grafted PDMS surfaces, time-
dependent measurements on the protein repelling characteristics of the PEG-grafted 
channels were performed.  The study was carried out by first filling the channels with a 
concentrated solution of fluorophore-labeled proteins and incubating the microfluidic 
device at 37 ˚C for 1 hour.  In our studies, two fluorophore-labeled proteins, avidin and 
fibronectin, were utilized.  The resulting protein-contaminated device was then cleaned 
by flushing a PBS solution through the channels.  Finally, the nonspecific absorption of 
the fluorophore-labeled proteins was quantified using fluorescent microscopy.  For each 
channel, more than 30 fluorescent measurements were carried out at different locations 
and averaged.  
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Figure A-3:  Fluorescent micrographs of PEG-grafted PDMS channels preserved at different time after treating the 
channels with concentrated fluorophore-labeled protein solutions followed by PBS washing  
 
The time-dependent profiles for the protein-repelling characteristics of the channels are 
similar for both avidin and fibronectin solutions.  During the initial 24 hrs the protein-
repelling property of the channels improved progressively; thereafter, the protein-
repelling property reached steady state and lasted for more than two months.   This 
suggests the robust cross-linked silane layers bear well-oriented PEG chains exhibiting 
excellent protein-repelling properties.  The change in protein repellency over time 
occurred on a time scale similar to that observed for the temporal contact angle 
measurements.   
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Figure A-4:  Fluorescent intensity of PEG-grafted channels after exposure to florescein-labeled avidin and Alexa 
5940labeled fibronectin 
Cell Adhesion 
Being able to specifically control cell immobilization and passivation would be beneficial 
to many types of cell cultures, cellular assays, and tissue engineering studies in 
microfluidic systems.  Tripeptide RGD is the smallest active fragment found in the 
extracellular matrix and is known to be an important ligand for cell immobilization 
through the RGD-integrin interaction (91).  The RDG-grafted channels were produced to 
test the feasibility of immobilizing cells in PDMS-based microfluidic channels.  A427 
cells (colon cancer cell line, ATCC) suspended in Dulbecco's modified Eagle medium 
(DMEM) cell culture media (Invitrogen) were introduced into the RGD-grafted channels, 
and allowed to incubate at 37 °C for 4 h.  Culture medium was then used to slowly flush 
out unattached A427 cells.  As shown in Figure A-5 a large number of A427 cells were 
immobilized on the RGD-grafted microchannels.  Similar tests are also performed in 
amine-grafted, PEG-grafted, and unmodified PDMS channels for comparison.  While 
some cells are attached to the channel walls in the amine-grafted channels, no cells were 
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immobilized in the PEG-grafted channel s. The unmodified PDMS channel retained very 
few cells,  
 
Figure A-5:  Optical micrographs showing enhanced cell adhesion in the RGD-grafted channel and cell passivation in 
the PEG-grafted channels.  Unmodified PDMS channel serves as control.   
Immunoassay 
Immunoassays are used to detect protein molecules with high selectivity and specificity. 
A conventional immunoassay is generally carried out in a 96-well plate, using microliter-
level samples. Performing a miniaturized immunoassay on a microfluidic device offers 
the advantages of lower sample and reagent consumption, enhanced reaction efficiency, 
reduced operation time, and a portable point of care platform. The PSCA-grafted 
channels were utilized to demonstrate an immunoassay for detection and quantification of 
a prostate cancer biomarker, anti-PSCA.  The PSCA-grafted channels trapped the anti-
PSCA molecules from anti-PSCA solutions (PBS, pH 7.4) of three different 
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approach is simple and convenient for routine analytical applications in chemistry and 
biology laboratories without additional equipment. In addition, the resulting surface 
modifications exhibit great stability. We have also successfully introduced functional 
groups, including PEG, amino group, isothiocyanate, peptide, and proteins onto the 
surfaces of microfluidic channels.  The PEG-grafted channels are well suited for cell 
passivation, while the RDG-grafted channels showed improved cell adhesion.  
Introduction of amino and subsequent isothiocynate groups is especially useful for 
attachment of other molecules.   
Materials and Methods 
DI water (Milli-Q, Millipore, Bedford, MA) was used in all aqueous solutions, as well as 
for cleaning.  PDMS prepolymer RTV615 (AB kit) was purchased from General Electric 
Co. (Waterford, NY).  Hydrogen peroxide (Sigma-Aldrich, St, Louis, MO), 2-
[methoxy(polyethylenxy)propyl]-trimethoxysilane (90% Gelest, Morrisville, PA), (3-
aminopropyl)trimethoxysilane (97%, Sigma-Aldrich), thiophosgen (Sigma-Aldrich), 
arginine-glycine-aspartic acid (Sigma-Aldrich), fluorescein-labeled avidin (Fisher, 
Pittsburgh, PA), PBS (pH 7.4, Fisher), and Tris-buffer (pH 7.4, Fisher) were used as 
received.  Fibronectin (Invitrogen, Carlsbad, CA) was treated with AlexaFluo 594 
Labeling Kit (Invitrogen).  Bovine serum (Invitrogen) was treated with AlexaFluo 555 
Labeling Kit (Invitrogen).   
Surface Modifications 
Conversion of surface Si-CH3 groups into Si-OH was accomplished through an oxidative 
reaction.   A mixture of H2O/H2O2/HCl (5:1:1) was flowed through PDMS channels 
through the connected Tygon tubing for 5 min.  After the reaction was completed, the 
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channels were purged with DI water and dried using argon (5 psi), creating a surface 
covered with silanols.   
PEG-Grafted Microfluidic Channels 
2-[methoxy(polyethylenoxy)propyl]terimethoxysilane was injected into the silanol-
covered channel by a microsyringe and kept at ambient temperature for 30 min until the 
silanization reaction was complete.  DI water was continuously flowed through the 
channels to remove any unreacted silane, resulting in the final PEG-grafted channels.  
Amino-Grafted Microfluidic Channels 
(3-aminopropyl)-trimethoxy silane was injected into the silanol-covered channel by a 
mcirosyringe and kept at ambient temperature for 30 min until the silanization reaction 
was complete.  DI water was continuously flowed through the channels to remove any 
unreacted silane, resulting in the final amino-grafted channels. 
Isothiocyanate-Grafted Microfluidic Channels:   
Thiophosgen solution in acetonitrile (0.5%) was introduced into amino-grafted channels 
and heated to 40 ˚C for 20 min.  The channel was subsequently purged with with DI 
water and argon gas to obtain the final isothiocyanate-grafted channels.  
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Appendix  B 
Fabrication Protocols 
FDG Device Design  
 
Figure B-1:  Assembled FDG device 
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Figure B-2:  FDG device rounded channel flow layer mask 
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Figure B-3:  FDG device column flow layer mask 
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Figure B-4:  FDG device control layer mask 
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FDG Device Mold Fabrication 
I. Flow Mold--Rounded Channels 
a. Clean Wafers:  Rinse with acetone, isopropanol and dry  
b. Primer Wafers: 2 min hexamethyldisilazane (HMDS) vapor 
 treatment 
c. Spin AZ100:  1000 rpm for 60 sec; 136 rpm/sec ramp.  
Film thickness = 45 µm 
d. Pre-Exposure Bake: 90 sec 65 ˚C/ 5 min 115 ˚C/ 90 sec  65˚C 
e. Expose Wafer:  85 sec at 8mW/cm2 
f. Initial Develop:  2:1  DI water and AZ Developer till only thin film 
 is left  
g. Final Develop:  5:1 DI water and AZ developer till completion 
h. Hard Bake:   Ramp from 65 ˚C to 190 ˚C; Bake for 5 hr at 190 ˚C 
 
II. Flow Mold--Column 
a. Spin SU8-2050: 500 rpm for 15 sec; 136 rpm/sec ramp. 
3800 rpm for 1 min, 136 rpm/sec ramp 
Film thickness = 45 µm 
 
b. Pre-Exposure Bake: 90 sec 65 ˚C/ 5 min 95 ˚C/ 90 sec  65˚C 
c. Expose Wafer:  45 sec at 8mW/cm2 
d. Post-Exposure Bake: 90 sec 65 ˚C/ 10 min 95 ˚C/ 90 sec  65˚C 
e. Develop:   SU-8 developer till completion  
Rinse with acetone, isopropanol, and dry 
f. Hard Bake:   Bake for 1 hr at 150 ˚C 
 
III. Control Mold  
a. Spin SU8-2025: 500 rpm for 15 sec; 136 rpm/sec ramp. 
3200 rpm for 1 min, 136 rpm/sec ramp 
Film thickness = 25 µm 
 
b. Pre-Exposure Bake: 90 sec 65 ˚C/ 5 min 95 ˚C/ 90 sec  65˚C 
c. Expose Wafer:  45 sec at 8mW/cm2 
d. Post-Exposure Bake: 90 sec 65 ˚C/ 10 min 95 ˚C/ 90 sec  65˚C 
e. Develop:   SU-8 developer till completion  
Rinse with acetone, isopropanol, and dry 
f. Hard Bake:   Bake for 1 hr at 150 ˚C 
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FDG Device: Device Fabrication 
1. TMCS Treat Molds:  Expose flow mold and  control mold to  
trimethylchlorosilane(TMCS) for 2 min 
2. Prepare Flow Layer: Combine 5:1 GE 615 RTV (30g A: 6 g B) 
Mix in hybrid mixer: 3 min mix/ 5 min degas 
Pour 32 g 5:1 onto flow mold 
Degas for 30 min in bell jar 
3. Prepare Control Layer:  Start while flow layer is degassing 
Combine 20:1 GE 615 RTV (20 g A: 1 g B) 
Mix in hybrid mixer: 3 min mix/ 5 min degas 
Pour 5 ml 20:1 onto control mold 
Spin at 1800 rpm for 75 sec, 136 rmp/sec ramp 
Let PDMS relax for 30 min before curing 
4. Cure Flow Layer:   Bake for 60 min at 80˚C 
5. Cure Control Layer: Bake for 45 min at 80˚C 
6. Control/Flow Bonding: Remove flow layer from mold 
Punch inlet and outlets with 20 gauge punch 
Cut devices out and clean with tape 
Align flow layer onto control layer 
Bake for 60 min at 80˚C 
 
7. Prepare Blank  Layer: Start While flow/control bonding 
Combine 20:1 GE 615 RTV (20 g A: 1 g B) 
Mix in hybrid mixer: 3 min mix/ 5 min degas 
Pour 5 ml 20:1 onto clean glass slide 
Let PDMS relax for 10 min before curing 
Bake for 30 min at 80˚C 
8. Assemble Device:  Remove bonded device from control mold 
Punch control inlets with 20 gauge punch 
Clean with tape 
Place bonded device onto blank layer  
Remove trapped air bubbles 
Cure assembled device at 80˚C for 24hr 
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PFPE DNA Synthesizer Design 
 
Figure B-5:  Assembled PFPE DNA synthesizer device 
 
 
Figure B-6:  PFPE DNA synthesizer rounded channel flow layer mask 
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Figure B-7:  PFPE DNA synthesizer column flow layer mask 
 
 
Figure B-8:  PFPE DNA synthesizer control layer mask  
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PFPE DNA Device Mold Fabrication 
I. Flow Mold--Rounded Channels 
a. Clean Wafers:  Rinse with acetone, isopropanol and dry  
b. Primer Wafers: 2 min hexamethyldisilazane (HMDS) vapor 
 treatment 
c. Spin AZ100:  1000 rpm for 60 sec; 136 rpm/sec ramp.  
Film thickness = 45 µm 
d. Pre-Exposure Bake: 90 sec 65 ˚C/ 5 min 115 ˚C/ 90 sec  65˚C 
e. Expose Wafer:  85 sec at 8mW/cm2 
f. Initial Develop:  2:1  DI water and AZ Developer till only thin film 
 is left  
g. Final Develop:  5:1 DI water and AZ developer till completion 
h. Hard Bake:   Ramp from 65 ˚C to 190 ˚C; Bake for 5 hr at 190 ˚C 
 
II. Flow Mold--Column 
a. Spin SU8-2050: 500 rpm for 15 sec; 136 rpm/sec ramp. 
3800 rpm for 1 min, 136 rpm/sec ramp 
Film thickness = 45 µm 
 
b. Pre-Exposure Bake: 90 sec 65 ˚C/ 5 min 95 ˚C/ 90 sec  65˚C 
c. Expose Wafer:  45 sec at 8mW/cm2 
d. Post-Exposure Bake: 90 sec 65 ˚C/ 10 min 95 ˚C/ 90 sec  65˚C 
e. Develop:   SU-8 developer till completion  
Rinse with acetone, isopropanol, and dry 
f. Hard Bake:   Bake for 1 hr at 150 ˚C 
 
III. Control Mold  
a. Spin SU8-2025: 500 rpm for 15 sec; 136 rpm/sec ramp. 
3200 rpm for 1 min, 136 rpm/sec ramp 
Film thickness = 25 µm 
 
b. Pre-Exposure Bake: 90 sec 65 ˚C/ 5 min 95 ˚C/ 90 sec  65˚C 
c. Expose Wafer:  45 sec at 8mW/cm2 
d. Post-Exposure Bake: 90 sec 65 ˚C/ 10 min 95 ˚C/ 90 sec  65˚C 
e. Develop:   SU-8 developer till completion  
Rinse with acetone, isopropanol, and dry 
f. Hard Bake:   Bake for 1 hr at 150 ˚C 
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PFPE DNA Device: Device Fabrication 
1. TMCS Treat Molds:  Expose flow mold, control mold, reservoir  
mold, and one blank wafer to  
trimethylchlorosilane(TMCS) for 2 min 
2. Prepare Flow Layer: Combine 5:1 GE 615 RTV (30g A: 6 g B) 
Mix in hybrid mixer: 3 min mix/ 5 min degas 
Pour 32 g 5:1 onto flow mold 
Degas for 30 min in bell jar 
3. Prepare Control Layer:  Start while flow layer is degassing 
Combine 20:1 GE 615 RTV (20 g A: 1 g B) 
Mix in hybrid mixer: 3 min mix/ 5 min degas 
Pour 5 ml 20:1 onto control mold 
Spin at 1800 rpm for 75 sec, 136 rmp/sec ramp 
Let PDMS relax for 30 min before curing 
4. Cure Flow Layer:   Bake for 60 min at 80˚C 
5. Cure Control Layer: Bake for 45 min at 80˚C 
6. Control/Flow Bonding: Remove flow layer from mold 
Punch inlet and outlets with 20 gauge punch 
Cut devices out and clean with tape 
Align flow layer onto control layer 
Bake for 60 min at 80˚C 
 
7. Prepare Blank  Layer: Start While flow/control bonding 
Combine 20:1 GE 615 RTV (20 g A: 1 g B) 
Mix in hybrid mixer: 3 min mix/ 5 min degas 
Pour 5 ml 20:1 onto clean glass slide 
Let PDMS relax for 10 min before curing 
Bake for 30 min at 80˚C 
8. Assemble Device:  Remove bonded device from control mold 
Punch control inlets with 20 gauge punch 
Clean with tape 
Place bonded device onto blank layer  
Remove trapped air bubbles 
Cure assembled device at 80˚C for 24hr 
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PDMS-Based Parallel DNA Synthesizer Design 
 
Figure B-9:  Assembled PDMS-based parallel DNA synthesizer 
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Figure B-10:  PDMS-based parallel DNA synthesizer rounded channel flow layer mask 
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Figure B-11:  PDMS-based parallel DNA synthesizer herringbone mixer mask 
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Figure B-12 PDMS-based parallel DNA synthesizer binary tree and column channel flow layer mask 
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Figure B-13:  PDMS-based parallel DNA synthesizer control layer mask 
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PDMS-Based Parallel DNA Synthesizer: Mold Fabrication 
I. Flow Mold--Rounded Channels 
a. Clean Wafers:  Rinse with acetone, isopropanol and dry  
b. Primer Wafers: 2 min hexamethyldisilazane (HMDS) vapor 
 treatment 
c. Spin AZ100:  1000 rpm for 60 sec; 136 rpm/sec ramp.  
Film thickness = 45 µm 
d. Pre-Exposure Bake: 90 sec 65 ˚C/ 5 min 115 ˚C/ 90 sec  65˚C 
e. Expose Wafer:  85 sec at 8mW/cm2 
f. Initial Develop:  2:1  DI water and AZ Developer till only thin film 
 is left  
g. Final Develop:  5:1 DI water and AZ developer till completion 
h. Hard Bake:   Ramp from 65 ˚C to 190 ˚C; Bake for 5 hr at 190 ˚C 
 
II. Flow Mold--Column 
a. Spin SU8-2050: 500 rpm for 15 sec; 136 rpm/sec ramp. 
3800 rpm for 1 min, 136 rpm/sec ramp 
Film thickness = 45 µm 
 
b. Pre-Exposure Bake: 90 sec 65 ˚C/ 5 min 95 ˚C/ 90 sec  65˚C 
c. Expose Wafer:  45 sec at 8mW/cm2 
d. Post-Exposure Bake: 90 sec 65 ˚C/ 10 min 95 ˚C/ 90 sec  65˚C 
e. Develop:   SU-8 developer till completion  
Rinse with acetone, isopropanol, and dry 
f. Hard Bake:   Bake for 1 hr at 150 ˚C 
 
III. Control Mold  
a. Spin SU8-2025: 500 rpm for 15 sec; 136 rpm/sec ramp. 
3200 rpm for 1 min, 136 rpm/sec ramp 
Film thickness = 25 µm 
 
b. Pre-Exposure Bake: 90 sec 65 ˚C/ 5 min 95 ˚C/ 90 sec  65˚C 
c. Expose Wafer:  45 sec at 8mW/cm2 
d. Post-Exposure Bake: 90 sec 65 ˚C/ 10 min 95 ˚C/ 90 sec  65˚C 
e. Develop:   SU-8 developer till completion  
Rinse with acetone, isopropanol, and dry 
f. Hard Bake:   Bake for 1 hr at 150 ˚C 
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PDMS-Based Parallel DNA Synthesizer: Device Fabrication 
1. TMCS Treat Molds:  Expose flow mold and control mold to 
trimethylchlorosilane(TMCS) for 2 min 
2. Prepare Flow Layer: Combine 5:1 GE 615 RTV (45 g A: 9 g B) 
Mix in hybrid mixer: 3 min mix/ 5 min degas 
Pour 52 g 5:1 onto flow mold 
Degas for 30 min in bell jar 
3. Prepare Control Layer:  Start while flow layer is degassing 
Combine 20:1 GE 615 RTV (20 g A: 1 g B) 
Mix in hybrid mixer: 3 min mix/ 5 min degas 
Pour 5 ml 20:1 onto control mold 
Spin at 1800 rpm for 75 sec, 136 rmp/sec ramp 
Let PDMS relax for 30 min before curing 
4. Cure Flow Layer:   Bake for 60 min at 80˚C 
5. Cure Control Layer: Bake for 45 min at 80˚C 
6. Control/Flow Bonding: Remove flow layer from mold 
Punch inlet and outlets with 20 gauge punch 
Cut devices out and clean with tape 
Align flow layer onto control layer 
Bake for 60 min at 80˚C 
 
7. Prepare Blank  Layer: Start While flow/control bonding 
Combine 20:1 GE 615 RTV (20 g A: 1 g B) 
Mix in hybrid mixer: 3 min mix/ 5 min degas 
Pour 5 ml 20:1 onto clean glass slide 
Let PDMS relax for 10 min before curing 
Bake for 30 min at 80˚C 
8. Assemble Device:  Remove bonded device from control mold 
Punch control inlets with 20 gauge punch 
Clean with tape 
Place bonded device onto blank layer  
Remove trapped air bubbles 
Cure assembled device at 80˚C for 24hr 
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32 Compartment DRAM Device Design 
 
Figure B-14:  Assembled 32 comparment DRAM device 
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Figure B-15 32 compartment DRAM device rounded channel flow layer mask 
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Figure B-16:  32 compartment DRAM device intermediate control layer mask 
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Figure B-17:  32 compartment DRAM device bottom level rounded channel flower layer mask  
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Figure B-18:  32 compartment DRAM bottom level control layer mask  
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32 Compartment DRAM Device: Mold Fabrication 
I. Top Flow Mold--Rounded Channels 
a. Clean Wafers:  Rinse with acetone, isopropanol and dry  
b. Primer Wafers: 2 min hexamethyldisilazane (HMDS) vapor 
 treatment 
c. Spin AZ100:  1000 rpm for 60 sec; 136 rpm/sec ramp.  
Film thickness = 45 µm 
d. Pre-Exposure Bake: 90 sec 65 ˚C/ 5 min 115 ˚C/ 90 sec  65˚C 
e. Expose Wafer:  85 sec at 8mW/cm2 
f. Initial Develop:  2:1  DI water and AZ Developer till only thin film 
 is left  
g. Final Develop:  5:1 DI water and AZ developer till completion 
h. Hard Bake:   Ramp from 65 ˚C to 190 ˚C; Bake for 5 hr at 190 ˚C 
 
II. Intermediate  Mold--Rounded Channels 
a. Clean Wafers:  Rinse with acetone, isopropanol and dry  
b. Primer Wafers: 2 min hexamethyldisilazane (HMDS) vapor 
 treatment 
c. Spin AZ100:  1000 rpm for 60 sec; 136 rpm/sec ramp.  
Film thickness = 45 µm 
d. Pre-Exposure Bake: 90 sec 65 ˚C/ 5 min 115 ˚C/ 90 sec  65˚C 
e. Expose Wafer:  85 sec at 8mW/cm2 
f. Initial Develop:  2:1  DI water and AZ Developer till only thin film 
 is left  
g. Final Develop:  5:1 DI water and AZ developer till completion 
h. Hard Bake:   Ramp from 65 ˚C to 190 ˚C; Bake for 5 hr at 190 ˚C 
 
III. Intermediate Control Mold 
a. Spin SU8-2050: 500 rpm for 15 sec; 136 rpm/sec ramp. 
3800 rpm for 1 min, 136 rpm/sec ramp 
Film thickness = 45 µm 
b. Pre-Exposure Bake: 90 sec 65 ˚C/ 5 min 95 ˚C/ 90 sec  65˚C 
c. Expose Wafer:  45 sec at 8mW/cm2 
d. Post-Exposure Bake: 90 sec 65 ˚C/ 10 min 95 ˚C/ 90 sec  65˚C 
e. Develop:   SU-8 developer till completion  
Rinse with acetone, isopropanol, and dry 
f. Hard Bake:   Bake for 1 hr at 150 ˚C 
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IV. Bottom Level Control Mold  
a. Spin SU8-2025: 500 rpm for 15 sec; 136 rpm/sec ramp. 
3200 rpm for 1 min, 136 rpm/sec ramp 
Film thickness = 25 µm 
 
b. Pre-Exposure Bake: 90 sec 65 ˚C/ 5 min 95 ˚C/ 90 sec  65˚C 
c. Expose Wafer:  45 sec at 8mW/cm2 
d. Post-Exposure Bake: 90 sec 65 ˚C/ 10 min 95 ˚C/ 90 sec  65˚C 
e. Develop:   SU-8 developer till completion  
Rinse with acetone, isopropanol, and dry 
f. Hard Bake:   Bake for 1 hr at 150 ˚C 
 
32 Compartment DRAM Device: Device Fabrication 
1. TMCS Treat Molds:  Expose Top flow mold, Intermediate control mold  
and bottom control mold to 
trimethylchlorosilane(TMCS) for 2 min 
2. Prepare Top Flow Layer: Combine 5:1 GE 615 RTV (30g A: 6 g B) 
Mix in hybrid mixer: 3 min mix/ 5 min degas 
Pour 32 g 5:1 onto flow mold 
Degas for 30 min in bell jar 
3. Prepare Int. Layer:  Start while flow layer is degassing 
Combine 20:1 GE 615 RTV (20 g A: 1 g B) 
Mix in hybrid mixer: 3 min mix/ 5 min degas 
Pour 5 ml 20:1 onto control mold 
Spin at 1800 rpm for 75 sec, 136 rmp/sec ramp 
Let PDMS relax for 30 min before curing 
4. Cure Top Flow Layer:  Bake for 60 min at 80˚C 
5. Cure Intermediate Layer: Bake for 45 min at 80˚C 
6. Int./Top Flow Bonding: Remove flow layer from mold 
Punch inlet and outlets with 20 gauge punch 
Cut devices out and clean with tape 
Align flow layer onto intermediate layer 
Bake for 60 min at 80˚C 
 
7. Prepare Bottom  Layer: Start while top/intermediate bonding 
Combine 20:1 GE 615 RTV (20 g A: 1 g B) 
Mix in hybrid mixer: 3 min mix/ 5 min degas 
Pour 5 ml 20:1 onto clean glass slide 
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Let PDMS relax for 10 min before curing 
Bake for 30 min at 80˚C 
8. Assemble Device:  Remove bonded device from intermediate mold 
Punch control and flow inlets with 20 gauge punch 
Clean with tape 
Place bonded device onto bottom control layer  
Remove trapped air bubbles 
Cure assembled device at 80˚C for 24hr 
9. Prepare Glass Slide: Wash glass slide using Micro-90 cleaner 
Rinse with DI water and dry 
10. O2 Plasma Treatment: 70 W, 300 mTorr, 15 sec 
11. Final Assembly:  Bond the device onto the glass slide 
Bake at 80˚C overnight 
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